Elizabeth Holmes SEC Deposition JULY 11, 2017 2 OF 4 redacted — Transcript
Full transcript
- 0:03We are back on the record at the
- 0:05beginning of media number two of
- 0:07Elizabeth Holmes. The time is 10:30.
- 0:10And Ms. Holmes, I just wanted to confirm
- 0:13we didn't have any substantive
- 0:15conversations during the break, did we?
- 0:17No.
- 0:18Okay, and I just want to make that
- 0:20give you that question after every break
- 0:22just to make sure that nothing was said
- 0:24off the record.
- 0:24Absolutely.
- 0:25Okay, so I'm going to hand to you what's
- 0:27been marked as Theranos so that 195.
- 0:38For everyone else this is 10.
- 0:47Exhibit 195
- 0:49purports to be
- 0:50a document entitled Theranos
- 0:52Confidential Summary Capitalization.
- 0:55The starting Bates number is TS-000603.
- 1:00I'll represent to you that this was
- 1:02produced by Theranos to the SEC as part
- 1:05of a binder that was provided by
- 1:07Theranos to Rupert Murdoch when he was
- 1:08considering whether to invest in
- 1:10Theranos in December 2014 and January
- 1:132015.
- 1:14The cover letter to the binder states
- 1:16that it was signed as of December 4th,
- 1:182014.
- 1:20You seen exhibit 195 before?
- 1:25You know, I I didn't recognize this
- 1:27first sheet sitting here now, but I'm
- 1:29I'm sure I did.
- 1:31What is exhibit 195?
- 1:35Um, it looks like our cap table
- 1:38and behind it a series of projections.
- 1:47Did you review exhibit 195 on or about
- 1:51December 4th, 2014?
- 1:55Um,
- 1:57I know I I don't
- 1:59have memory of
- 2:00whether I reviewed it at that time, but
- 2:02I I know I've seen it.
- 2:05So, I'm actually
- 2:06just going to start on the first page,
- 2:08which is 603. Is the Bates number at the
- 2:11bottom?
- 2:12Yes.
- 2:12Uh is this an accurate reflection of
- 2:14Theranos' capital raising since it's um
- 2:17since the company
- 2:19was founded?
- 2:23As of what period of time?
- 2:26Um I guess as of 2013. That's a good
- 2:28date.
- 2:30As of 2013.
- 2:32Um
- 2:37No.
- 2:39Um
- 2:41I think this was as of
- 2:43a later period of time.
- 2:46Okay. So, what period What was the date
- 2:49at which do you this document was
- 2:50prepared at then?
- 2:52The the C2 didn't happen until
- 2:55um
- 2:572014 was the first part of the C2.
- 3:02Okay. So,
- 3:03um so you think that this is an accurate
- 3:05reflection of the capital raising the
- 3:07company did as of 2014?
- 3:09No.
- 3:11No.
- 3:12No.
- 3:12Okay. So,
- 3:14what happened in 2014?
- 3:17Oh, I'm sorry. As of 2014, I was missing
- 3:19my years. Yes, I think that as of the
- 3:21end of 2014, this this looks about
- 3:23right.
- 3:23This looks about right. But how much was
- 3:25raised during the C2 round?
- 3:29Um it was it was several hundred million
- 3:31dollars. I I don't know exactly the a
- 3:33number. Um
- 3:36I I think it was it was over 500
- 3:37million.
- 3:38Okay. So, if it was over 500 million,
- 3:40then um
- 3:42do you think that this chart maybe isn't
- 3:44an accurate reflection at least um it
- 3:46doesn't include some of the C2 round?
- 3:49Um correct. It doesn't include some of
- 3:51the C2. I I don't know exactly when this
- 3:53was prepared and what period of time it
- 3:55was supposed to be reflective of.
- 3:57Okay.
- 3:58Um but you think that the the total for
- 4:00the C2 round would have been something
- 4:02like over 500 million dollars.
- 4:04I believe so.
- 4:07Um so I just want to focus for a period
- 4:11uh
- 4:12on the C1 and C2 rounds.
- 4:15What were those financing rounds? What
- 4:17was the purpose of raising money during
- 4:19those rounds?
- 4:22Um
- 4:24so they were they were different at
- 4:26different points in time. C1
- 4:29uh we began
- 4:32developing strategic relationships with
- 4:35um
- 4:36long-term shareholders and um some of
- 4:39the hospital systems that we wanted to
- 4:41partner with came in through a fund and
- 4:45then C2 we had decided that we wanted to
- 4:48try to structure Theranos as a private
- 4:50company and we were looking for
- 4:54family-owned businesses or
- 4:55family-controlled companies um and
- 4:58leadership who
- 5:00wanted to invest in something for the
- 5:02really long term and we identified a
- 5:05group of people to try to bring in for
- 5:06that.
- 5:07So you said for C the C1 round, I just
- 5:10want to make sure that I understand. For
- 5:12the C1 round
- 5:14um that was mainly money coming from
- 5:16strategic partners like hospitals and
- 5:19When it started.
- 5:20Yes.
- 5:20Yeah, I mean it we had also um
- 5:23another family that invested through one
- 5:26of the funds that came in in in C1 and
- 5:30um then a couple of the hospital systems
- 5:33that we were hoping to partner with came
- 5:35in in that as well.
- 5:36Which family came in in C1 that you're
- 5:39thinking of?
- 5:39This family.
- 5:41And did family and uh the hospital
- 5:44systems they all come in through Peer
- 5:45Venture Group?
- 5:46They did.
- 5:46What is Pure Venture Group?
- 5:49It is a fund.
- 5:51Um
- 5:52what was your relationship with them?
- 5:55For a long time. And I I met him through
- 5:59Okay. And so how did that relationship
- 6:01come about?
- 6:03You know, who initiated talks of um
- 6:07uh
- 6:07part potentially investing in Theranos.
- 6:10Um you know, and what happened? How did
- 6:12you How did How were you able to get
- 6:14that investment from Pure Venture Group?
- 6:16The first one was in 2010. So I I don't
- 6:19remember specifically, but I My memory
- 6:22is that had expressed interest about
- 6:24investing in Theranos and specifically
- 6:27sort of having a fund that focused on
- 6:29investing in Theranos and strongly
- 6:31encouraged uh me to meet with him and
- 6:35the people that I think he was working
- 6:36to raise money from and um
- 6:39and to invest.
- 6:41Okay. And then you mentioned for C2,
- 6:44that was mainly for um
- 6:47you'd raise money in order to establish
- 6:49a long-term shareholder base. Is that
- 6:52right? Can you explain a little bit more
- 6:53about that?
- 6:54Yeah. Over over a period of time, we
- 6:57became convinced that becoming a private
- 6:59company for the long term would best
- 7:01allow us to do something that was going
- 7:03to be a very long-term
- 7:05venture. And so we were trying to find
- 7:07investors who wanted to invest in
- 7:10private companies and wanted to make
- 7:12really long-term investments and
- 7:15generally who had built family
- 7:16companies. And um so we identified a
- 7:19series of people who had done that and
- 7:22went to meet with them to talk about
- 7:25this vision. And And so that was That
- 7:27was the majority of the C2.
- 7:31What was the money that you raised
- 7:32during the C1 and C2 rounds used for?
- 7:36Um a lot of R&D and operational
- 7:41investments. Like we built a a big
- 7:44manufacturing facility in Newark,
- 7:46California where we do our own injection
- 7:48molding and machining and reagent
- 7:50production and um
- 7:54um
- 7:57primarily those two things.
- 8:00Going into both of these rounds of
- 8:01financing, did you have a particular
- 8:03target that you were aiming to raise?
- 8:06And what were those targets?
- 8:08I I don't I don't know. I'm I'm sure we
- 8:11did. I I can't remember exactly what the
- 8:14what the numbers were. Um I I think it
- 8:19it was also a bit dynamic in terms of
- 8:21responding to interest and people who
- 8:23had expressed interest in being
- 8:25shareholders in the company.
- 8:29So if you look um at the price at which
- 8:32the shares were sold during these two
- 8:35rounds, um the first C1 round that took
- 8:38place in 2010, the price was $3 a share.
- 8:43Uh the second C1 round, it went up to
- 8:45$15. What um
- 8:49what precipitated the the change in
- 8:50price?
- 8:54So my my memory is that that was um
- 8:58a a price per share that was established
- 9:02uh through the relationships with the
- 9:04retail pharmacy partners who were
- 9:06thinking about what the value of
- 9:08Theranos could be um if we had these
- 9:12retail frameworks in place and that
- 9:13that's where that that number came from.
- 9:17So are you are you saying then that the
- 9:19retail uh partners um actually valued
- 9:23Theranos at the $15 a share?
- 9:26I don't know if they valued it, but
- 9:29to the extent there were provisions in
- 9:32the contract that gave them potential
- 9:34rights to equity, that was the value
- 9:37that they put on the equity rights that
- 9:39they had.
- 9:40Who came up with the $15 per share
- 9:42valuation?
- 9:46I I don't I don't know.
- 9:48I'm not sure.
- 9:50Was that a number that Theranos
- 9:51requested of its retail partners?
- 9:57You know, I don't remember. I I know
- 9:59there was a lot of work with the retail
- 10:02partners to create models together of
- 10:04what this could be. I'm not sure if
- 10:08I'm not sure who who settled on that
- 10:10number in the end.
- 10:13Was it negotiated?
- 10:15I don't think so.
- 10:19Who would know the answer to that
- 10:20question?
- 10:23I mean, I'm assuming our team could look
- 10:26back at at documents and and try to
- 10:28figure it out. I
- 10:30I don't remember. Um
- 10:34I'm not sure.
- 10:35Would you have been involved in those
- 10:36discussions
- 10:38with your retail partners?
- 10:39I I would have, yes.
- 10:41Would Sunny Balwani have been involved?
- 10:42Yes.
- 10:49Okay.
- 10:50Um I'm going to hand you another
- 10:52document.
- 10:54You can put that one aside.
- 11:26I'm handing to you what's been marked as
- 11:28Theranos 608 196.
- 11:35Exhibit 196 purports to be
- 11:37uh a spreadsheet.
- 11:39Uh the title at the top is
- 11:42detailed um
- 11:442917.
- 11:45Starting base number is
- 11:48TS-0558077.
- 11:52Have you seen Exhibit 196 before?
- 11:57You know what? I don't remember seeing
- 11:58this version, but I I recognize it as as
- 12:02our cap table.
- 12:07Did you review Exhibit 196 on or around
- 12:10February 9th, 2017?
- 12:14I I don't remember doing that.
- 12:17I'll represent to you that that's the
- 12:19date at which um
- 12:21that appears on the document uh and
- 12:23would have been around the date that
- 12:24Theranos produced the document to the
- 12:26SEC.
- 12:27Yep.
- 12:28So,
- 12:30I want to focus on some of the C1 and C2
- 12:33investors on this list. So, if you go
- 12:35down, uh
- 12:37there's an investor called Bendel Fund.
- 12:39Do you see that on the first page?
- 12:43I do.
- 12:45Uh
- 12:46and they invested like
- 12:48in 249,998
- 12:51shares um in the C2 round.
- 12:54Who is the the Bendel Fund?
- 12:57Um I believe uh this is
- 13:01his he's an individual um company.
- 13:07How do you know him?
- 13:08How did you get to know him?
- 13:10I met him through this process of trying
- 13:12to find
- 13:14family
- 13:15controlled companies and investors um
- 13:17and
- 13:18I'm trying to remember who made the
- 13:20introduction. He he knows a number of
- 13:23people affiliated with the company um
- 13:26I'm not quite sure who made the the
- 13:28final introduction to him.
- 13:31Who does he know at the company?
- 13:34I'm
- 13:35He knows some of our investors. He knows
- 13:37some of our board members specifically.
- 13:40I
- 13:41I'm just not sure who who made the first
- 13:43introduction to him.
- 13:47Who are the investors that he knew?
- 13:49I I My understanding is he knows he
- 13:52knows most of our C2 investors, the
- 13:54other large family
- 13:55investors.
- 13:59What about Central Valley
- 14:00Administrators? Who are they?
- 14:05It's on the second page.
- 14:06I think that is that Walgreens
- 14:09introduced us to when they were talking
- 14:12about deploying in California.
- 14:16Who's
- 14:17Okay, and what Why was he
- 14:20interested in Theranos?
- 14:22I I think he really believes in I'm
- 14:27the need for lower cost, more
- 14:29distributed testing.
- 14:32Were you in talks to
- 14:35partner with him in any way?
- 14:37It was our hope that had we deployed in
- 14:40Los Angeles with Walgreens, we would
- 14:42work with his physician groups.
- 14:44So was this Was he also considered a
- 14:46strategic partner, a possible strategic
- 14:49partner?
- 14:49Yes.
- 14:51So in other words, even though he
- 14:52invested in the C2 round, it looks like
- 14:55there were also also opportunities for
- 14:57strategic partners to come in in the C2
- 14:59round in addition to some of these
- 15:00families.
- 15:02I'm
- 15:04I'm trying to think if there were any
- 15:05others beside him. I know generally the
- 15:07the focus of C2 was the families. I'm
- 15:12But had there been a
- 15:14a strategic I mean there's no reason why
- 15:16we wouldn't have looked at that in the
- 15:18context of involvement.
- 15:21If you turn the page to page three,
- 15:27uh, what about Dynasty Financial?
- 15:31It's also a C2 round investor.
- 15:33I I believe that's the DeVos family.
- 15:36It's the DeVos family. How did you know
- 15:38them?
- 15:40I met them uh
- 15:41at a
- 15:43um conference for family-controlled
- 15:46companies
- 15:47um and
- 15:49um
- 15:50I talked to him about our vision.
- 15:53What conference is that?
- 15:55That was the conference
- 15:58I think it was in Chicago.
- 16:00And what is So they invited a number of
- 16:02uh family offices to come for a
- 16:05conference?
- 16:06I I think so, yes.
- 16:07that happen?
- 16:09Um in the fall of 2014
- 16:13or maybe winter of 2014.
- 16:15Why did you attend?
- 16:17I was asked to speak at it.
- 16:18What did you speak about?
- 16:20had asked me to serve on a panel, I
- 16:22think about innovation. Um I I don't
- 16:24remember what I talked about. It was I'm
- 16:27sorry. Uh
- 16:28Uh you don't recall what you talked
- 16:29about at that conference?
- 16:32I don't. I mean I I guess. Um
- 16:35I don't remember it specifically.
- 16:36Did you meet uh the DeVos family at that
- 16:38conference?
- 16:39I did.
- 16:41Who was your main contact there?
- 16:44Um initially it was now it's
- 16:47He was
- 16:48She's my understanding and her boss.
- 16:50Is he or
- 16:52I I I think so. I'm not sure.
- 16:55Uh
- 16:55what about Hall Black Diamond 2, which
- 16:58is towards the bottom of the of page
- 17:00three?
- 17:03Um
- 17:04Who are they?
- 17:06So that is a fund that was created for
- 17:11one of the limited partners of Black
- 17:13Diamond to be able to have direct uh
- 17:16holdings in Theranos.
- 17:19And who
- 17:20Black Diamond and I I think a successful
- 17:22business person um
- 17:24How did you meet him?
- 17:27I I believe I met him after he had
- 17:30invested in Black Diamond's fund that
- 17:32invested in Theranos. Um so through
- 17:35Black Diamond.
- 17:36And um was there somebody else at Black
- 17:38Diamond that you knew prior to uh this
- 17:42relationship? Who
- 17:44Um
- 17:45If you turn the page to page four
- 17:49at the very top
- 17:51who is
- 17:52That is my understanding is it's the
- 17:55um foundation affiliated with his
- 17:58family.
- 17:59And who's
- 18:00Uh he's a a
- 18:02businessman.
- 18:03Um when did you first contact with him?
- 18:10Um
- 18:11I think in
- 18:132014.
- 18:15Um but I'm not completely sure.
- 18:18How did you meet him?
- 18:20I met him
- 18:22um
- 18:26I I I
- 18:28I think I met him at
- 18:31um someone's house and we started having
- 18:34a conversation about health care.
- 18:37Do you recall whose house you met him
- 18:39at?
- 18:40I think it was um
- 18:41a Silicon Valley venture capitalist.
- 18:45What did you talk about?
- 18:48We talked about the need to make lab
- 18:51testing lower cost and more accessible
- 18:53and um
- 18:56the need to
- 18:57invest in technologies
- 18:59that can leapfrog over traditional lab
- 19:03infrastructure kind of like cell phones
- 19:05did over landlines and how important
- 19:08that's going to be for for for care.
- 19:11Is he in the health care business?
- 19:14He is, yes.
- 19:16Uh
- 19:16what is his business?
- 19:18And also a number of other businesses.
- 19:22Um he owns retail grocery store. Um that
- 19:24include pharmacies um and
- 19:28many other businesses.
- 19:29Did you ever have any discussions with
- 19:32about uh partnering with his businesses?
- 19:35We did.
- 19:36And how did those
- 19:37how did those discussions go?
- 19:40They were very positive. Um he has a
- 19:43foundation that we've interacted with
- 19:45most closely that's talked to us about a
- 19:48number of different projects including
- 19:49our our current focus on on Zika virus
- 19:52testing in
- 19:54low-income and distributed areas.
- 19:56Did you end up entering into a contract
- 19:57with him or his companies?
- 20:00I I don't know if we have a contract
- 20:02with their foundation. I'm not sure.
- 20:06Not his his laboratory um business.
- 20:12Um
- 20:15Okay. Um
- 20:16let's turn page to
- 20:20page six.
- 20:25Towards the top of the page um there's
- 20:27an investor called Sandbox Financial
- 20:29Company Sandbox
- 20:31Co-Investment Fund.
- 20:33Who are they?
- 20:35So I think these are two different ones.
- 20:37Are they two different ones?
- 20:39Yeah.
- 20:43Okay, then I'm asking about Sandbox
- 20:45Co-Investment Fund since they're C1
- 20:46investor.
- 20:47Yes, so they are
- 20:50um
- 20:51as I understand it the fund that manages
- 20:54the investments for the Blue Cross Blue
- 20:56Shield Association.
- 20:58And how did you get in contact with
- 21:00them?
- 21:02So this was
- 21:03I think in 2010 and I
- 21:08I'm not sure. I think it was our board
- 21:10member Robert Shapiro was an advisor to
- 21:14the Blue Cross Blue Shield Association
- 21:16fund and part of Sandbox and I think he
- 21:18made the introduction. It
- 21:20may have come from somewhere else, um
- 21:22but
- 21:23that sounds right.
- 21:25What was your understanding of why they
- 21:27were interested in investing at
- 21:28Theranos?
- 21:30Because the lab companies have been
- 21:32charging them extremely high rates and
- 21:35they've been negotiating for years to
- 21:37try to break up the
- 21:39um
- 21:40duopoly of pricing between Quest and
- 21:42LabCorp and they thought that we could
- 21:44build a low a lab company that would
- 21:47offer really low cost testing.
- 21:52And then further down the page, um Soda
- 21:55Spring Partners.
- 21:58Who are they?
- 22:00That is Alice Walton, part of the Walton
- 22:02family.
- 22:03Part of the Walton family. And how did
- 22:04you get to know the Walton family?
- 22:07Um
- 22:15I can't remember the first introduction.
- 22:17I think my first contact with them was
- 22:19with Greg Penner,
- 22:20um who's the the chairman at Walmart. I
- 22:24I don't know who introduced me to him.
- 22:27He He was certainly one of the families
- 22:29that as we brainstormed on who were the
- 22:32the types of people that would want to
- 22:33be part of taking something like this on
- 22:36um that that we thought about.
- 22:40When you're
- 22:41I think you just said he was one of the
- 22:43people. So, do you mean um
- 22:45the Walton family or do you mean
- 22:46Walmart?
- 22:48Well, I What I was referring to was was
- 22:50it the Walton family is one of the the
- 22:52great, you know,
- 22:53sort of family controlled businesses
- 22:55that's been built in this country. Um
- 22:58we absolutely were also interested in
- 23:00the relationship with Walmart. Um and
- 23:03was that was early on part of our
- 23:04discussions with with Greg.
- 23:07Part of your discussions with Greg were
- 23:09to potentially partner with Walmart in
- 23:11the retail pharmacy space?
- 23:13Yes.
- 23:15And specifically I think he wanted them
- 23:17to evaluate the promise of this.
- 23:19Did you ever enter into a contract with
- 23:21Walmart?
- 23:22I don't think so.
- 23:23Did you have any other business
- 23:24relationship with them aside from having
- 23:26these discussions?
- 23:29Prior to meeting Greg, we'd had
- 23:32a fair amount of interaction with them.
- 23:34There was no formal contract about how
- 23:37you would
- 23:38roll out the concept was
- 23:40$4 lab testing like they'd done $4
- 23:43pharmacy prescriptions.
- 23:46And did anything come of that? Did you
- 23:48end up
- 23:50either piloting or rolling out any
- 23:52services even if you didn't have a
- 23:53contract?
- 23:54No, we were prohibited under the terms
- 23:56of our Walgreens and Safeway contracts
- 23:58initially from doing that for some
- 24:00period of time.
- 24:02I
- 24:03Did Greg Penner introduce you to Alice
- 24:05Walton?
- 24:06Or did someone else introduce you to
- 24:08him?
- 24:09Um
- 24:11I I believe
- 24:12was the point person for Alice. I I met
- 24:15Alice
- 24:16um
- 24:18at a dinner
- 24:19separately. I think she was sitting near
- 24:22me. Um
- 24:24Um
- 24:27But but I know
- 24:28um works with her.
- 24:31Do you ever meet Rob Walton?
- 24:33I did.
- 24:33What what what do you recall about that?
- 24:36Um
- 24:37I
- 24:39recall talking to him about this concept
- 24:42of $4 lab testing and the vision for
- 24:44what we were trying to do
- 24:46in the lab space in terms of access to
- 24:50health information.
- 24:51I recall telling him about
- 24:55the technology we were working to
- 24:57implement
- 24:58and I recall initially focusing on
- 25:01you know, what this could be if we did
- 25:03have the opportunity at some point to
- 25:05partner with Walmart and I mean then
- 25:07later he became an investor. He's Greg's
- 25:10father-in-law.
- 25:12How did he become an investor?
- 25:16Um
- 25:17so the
- 25:18what what vehicle or
- 25:20you know, is he on the list or was there
- 25:22an entity invested through?
- 25:24Yes, um the Madrone entity is is him and
- 25:28Greg and um
- 25:31the associated fund partners.
- 25:37So, um in looking through exhibit 196,
- 25:41we actually noticed that Rupert Murdoch
- 25:43doesn't appear on here.
- 25:46Um do you know why?
- 25:48Is he an investor?
- 25:51Or was he an investor in Theranos?
- 25:54He was an investor in Theranos, yes.
- 25:56So
- 25:58was he taken out? Is he still an
- 26:00investor in Theranos today?
- 26:02He is not.
- 26:03Is that the reason why he doesn't appear
- 26:05on this list?
- 26:06I don't know why he doesn't appear on
- 26:07this list.
- 26:08Do you know who prepares um you know,
- 26:10the capitalization table for Theranos?
- 26:13Or who maintains it?
- 26:14Um it's it's changed over time. It used
- 26:17to, I think now it's done by by one of
- 26:19our legal firms.
- 26:21Okay. But in the uh 2013-2014 time frame
- 26:25it would have you would have maintained
- 26:26it.
- 26:26I I believe so, yes.
- 26:30Um so, were you involved in discussions
- 26:32with um the investors in the C1 and C2
- 26:35round to invest in Theranos?
- 26:37I was.
- 26:38What was your involvement?
- 26:40Um I would talk about the kind of
- 26:43company we were trying to build, talk
- 26:45about the vision, talk about um why we
- 26:49were interested in structuring this as a
- 26:51private company and sort of the
- 26:52long-term nature of it and
- 26:55um what we thought we have the potential
- 26:58to do here.
- 27:00Were you involved in providing
- 27:02uh materials to them for their due
- 27:04diligence purposes?
- 27:07Um I I was involved.
- 27:10I
- 27:11just so I answer the question correctly,
- 27:13what what do you mean by that?
- 27:14So, were were you aware that these
- 27:16investors would sometimes request uh
- 27:19materials or documents from Theranos?
- 27:21Yes.
- 27:22And were you involved in compiling that
- 27:24information or collecting that
- 27:25information for them?
- 27:27I I don't know if I specifically did
- 27:29that, but I knew that the materials were
- 27:32going to investors.
- 27:34Okay. Would you review those materials
- 27:36or documents before they were sent to
- 27:37investors?
- 27:40You know, I I I would need to
- 27:43think about a specific instance to
- 27:46be able to speak about it specifically.
- 27:47I I certainly
- 27:49was generally aware of the the types of
- 27:51content that we were sending to
- 27:53investors.
- 27:54What what were the types of content that
- 27:55you were sending to investors?
- 27:58I mean, we we had a very
- 28:01um informal process in place, which was
- 28:04um
- 28:06you know, decks that we used for a
- 28:08number of different purposes in terms of
- 28:09slides we would share. They had data on
- 28:12the performance of our chemistries.
- 28:14Um
- 28:15we would share other information that we
- 28:18thought just gave people a perspective
- 28:20of
- 28:21what we were trying to do.
- 28:23Okay.
- 28:23Um it was it was
- 28:26it was a startup, so we didn't have the
- 28:28the systems in place to do this in a in
- 28:30a formal way.
- 28:32Uh did you would you sometimes be the
- 28:34person sending the materials to
- 28:36investors?
- 28:38Either through email or
- 28:40I I could have been. I I don't I can't
- 28:42sit here and say I remember a specific
- 28:44instance in which I did, but it it
- 28:46wouldn't surprise me if I did.
- 28:48What was Sunny Balwani's role in those
- 28:51discussions with investors?
- 28:54Um I would generally do the the first
- 28:57meeting or two and talk about the vision
- 28:59and then he would follow up on
- 29:01any questions that they had from a
- 29:02diligence perspective and
- 29:04um provide them with that information.
- 29:07Did he attend those initial meetings
- 29:09that you had with investors?
- 29:11Most of the time, yes.
- 29:13Did he participate in those
- 29:15meetings? Was he Would he be presenting
- 29:17material as well or was it mostly just
- 29:19you talking?
- 29:21The meetings that I was in which were
- 29:23sort of the initial meetings um
- 29:25we didn't frequently present anything.
- 29:27It was just discussion and and yes, he
- 29:28would be involved in the discussion as
- 29:30well.
- 29:31Was there anyone else from the company
- 29:32who was involved in those investor
- 29:34discussions besides you and Mr. Balwani?
- 29:37I I'm sure there were others in the room
- 29:39for certain meetings. I would I would
- 29:41need to think about a a specific meeting
- 29:43to be able to talk about who else was in
- 29:45there.
- 29:45Okay. Would there be others who would
- 29:47um
- 29:48be making a presentation to investors
- 29:51during those meetings? So I'm I'm more
- 29:53interested in the people who would have
- 29:54been
- 29:55speaking at those meetings. Can you
- 29:57think of anyone who would have besides
- 29:59you and Mr. Balwani who would have been
- 30:01speaking at those meetings?
- 30:02I mean if you could if you give me a
- 30:03specific meeting, I could I could try to
- 30:05think back to it. There was there was a
- 30:06lot of meetings over a period of many
- 30:08years. Um
- 30:10we had people to
- 30:13we were generally
- 30:15tried to respond to any questions that
- 30:17an investor had. So if they wanted to
- 30:19focus on a specific area, we might have
- 30:21had people who were specific to that
- 30:24area engage, but I I can't sit here and
- 30:27recall a
- 30:28specific example.
- 30:30Were there particular areas that uh you
- 30:33would present on and particular areas
- 30:35that Mr. Balwani would present on and
- 30:37what were those areas?
- 30:39Yeah, I I presented the vision, right?
- 30:41What we're trying to build, what we've
- 30:42invented, and what we think it could do.
- 30:44Yeah, um
- 30:45Sunny would present on our projections
- 30:49and what we thought it could mean
- 30:50financially and on the operations of the
- 30:53business, whether it be on manufacturing
- 30:56or the clinical lab.
- 30:59Uh when you were sitting in meetings
- 31:00with Mr. Balwani um and you're having
- 31:03these discussions with investors, were
- 31:04there times when
- 31:06um Mr. Balwani would present something
- 31:08to investors that you thought was not
- 31:10right or inaccurate?
- 31:14I don't I don't remember
- 31:17an instance in which that ever happened.
- 31:19I
- 31:20I I generally understood
- 31:23um
- 31:25at least what it what I saw to be the
- 31:26assumptions behind how he he
- 31:28characterized our potential.
- 31:31So, when you say you saw the assumptions
- 31:33behind how he would characterize your
- 31:35potential, what what did what do you
- 31:36mean by that?
- 31:38I mean, our our projections were
- 31:39generally based on an assumption that we
- 31:41would have a certain retail footprint
- 31:43and I knew that we had the ability to
- 31:46get that footprint if we executed and
- 31:49so I assumed that those numbers made
- 31:51sense in that context.
- 31:54So, you would you would have reviewed
- 31:55the assumptions before Mr. Balwani
- 31:58uh was presenting these financials to
- 32:00investors.
- 32:01Not not necessarily. Um I'm I'm sure
- 32:04sometimes I I did, but I um
- 32:07I'm not as a necessary normal operating
- 32:10cadence.
- 32:12But, you can't think of an instance in
- 32:13which Mr. Balwani would have presented,
- 32:15for instance, the financials to
- 32:16investors um that you thought was
- 32:19incorrect or inaccurate?
- 32:22You're talking about the projections?
- 32:23I'm talking about the financial
- 32:25projections now, yes.
- 32:27Not not at that time, no.
- 32:30Can you think of any instance in which
- 32:32um Mr. Balwani made any other inaccurate
- 32:35or incorrect statements to investors uh
- 32:37setting aside the financial projections?
- 32:42I mean, not not when I was in the room.
- 32:45That I can remember.
- 32:47Had he made an inaccurate or incorrect
- 32:49statement to investors, would you have
- 32:51corrected him?
- 32:52Absolutely.
- 32:54Um and were there times when Mr. Balwani
- 32:57corrected you while you were making your
- 32:58presentation to investors?
- 33:02I mean, he was not shy about jumping in
- 33:04on things that I would say. So, um
- 33:07he he was definitely very vocal in in
- 33:09those meetings.
- 33:14Was there ever a topic um
- 33:17in those discussions with investors in
- 33:18which you felt like you were
- 33:21not sufficiently familiar with it um and
- 33:24and so couldn't speak to it?
- 33:27Me personally?
- 33:28Yes.
- 33:28For sure.
- 33:29What what were those topics?
- 33:32I mean, this is why I deferred to other
- 33:33people on
- 33:36the operations of our clinical lab, on
- 33:38our operational infrastructure
- 33:40internally in terms of production, on
- 33:43financials and financial modeling. I
- 33:45didn't have any training or background
- 33:47in that.
- 33:48Were there any other areas?
- 33:51I'm sure there were. I mean, I'm
- 33:54I'm
- 33:56I'm
- 33:57I tried to be good in a couple of
- 33:59things, which generally have to do with
- 34:01inventing and sort of ideas and vision.
- 34:04I
- 34:05I
- 34:06I tried to surround myself with people
- 34:08who I thought were better than I was in
- 34:11in other areas.
- 34:13What about
- 34:14the product development area? Were you
- 34:16sufficiently familiar with that area to
- 34:18be able to speak to investors about it?
- 34:21In so far as the architecture of our
- 34:23technology, like the the idea of, for
- 34:26example, putting a robot in a
- 34:27distributed testing system, yes.
- 34:30Um in so far as
- 34:32how to interpret the data or the
- 34:34standards, I relied on on our teams.
- 34:38Okay. And so I think you said two things
- 34:41in terms of the data and what standards
- 34:43should be applied, you relied on your
- 34:45teams. So who was in charge of those two
- 34:47things at the company?
- 34:49So it depended on what data and what
- 34:52standards.
- 34:53From the perspective of R&D, it was our
- 34:57development or product leads who were
- 34:59the different team leads that
- 35:01were in place at different points in
- 35:02time. From the perspective of our
- 35:04clinical lab, it would
- 35:05So in the 2013 time frame that would
- 35:07have been are you talking about Was
- 35:09there another person that you mentioned
- 35:11earlier?
- 35:12Yeah, I'm trying to go back and remember
- 35:14who the team leads were in 2013 cuz it
- 35:17it evolved and we were generally trying
- 35:19to promote these scientists from within.
- 35:22I'm
- 35:23But yes, those are the types of people
- 35:25who
- 35:27would
- 35:29ensure that the assays were developed to
- 35:31the standards that we thought we were
- 35:34developing them to.
- 35:36Okay.
- 35:36Um
- 35:37And then you said the lab director for
- 35:39the clinical lab. So was that then in
- 35:41the 2013 time frame?
- 35:43time, yes.
- 35:44Okay.
- 35:45Um
- 35:46Would you
- 35:48be kept apprised of
- 35:51um what assays have been developed
- 35:54over the course of time? Was that
- 35:56something that you would be apprised of?
- 35:58It it was, yes. And we had sort of
- 36:00tracking spreadsheets at different
- 36:02periods of time to see, okay, how many
- 36:04assays have sort of hit these different
- 36:06steps that we thought were required to
- 36:09develop and validate the assays.
- 36:11Okay. Um and then would you also be kept
- 36:13apprised of how many of those have been
- 36:15transferred onto the hardware, onto the
- 36:17devices, the analyzers that would be
- 36:19analyzing the blood samples?
- 36:23I don't know that we ever tracked it
- 36:25like that.
- 36:26Um
- 36:27we always thought about it as you're
- 36:29you're de-
- 36:30developing chemistries that could work
- 36:32on small samples. And with these
- 36:34standardized tube types, you didn't need
- 36:36all the different color tubes.
- 36:38Um
- 36:39and then you could put them on two
- 36:40different hardware platforms. And that
- 36:43ultimately became a business decision
- 36:45around the business model that we
- 36:48decided to go with.
- 36:50So, you just said that you didn't really
- 36:51think about that too much. But why
- 36:53wasn't that important to the process?
- 36:56You know, actually putting the assays
- 36:57onto the machine because the machine is
- 36:59the
- 37:00the device that would actually be
- 37:01conducting the the testing.
- 37:03Um well, you you first need to know what
- 37:06your deployment is, right? So, if you're
- 37:08trying to deploy for a pharmaceutical
- 37:11clinical trial and you're trying to put
- 37:13machines in a distributed setting, then
- 37:15getting those assays validated on those
- 37:18machines makes sense.
- 37:20Um
- 37:20and during that period of time, we were
- 37:23mostly trying to develop a wide assay
- 37:26menu to show that
- 37:28this belief we had that any of these
- 37:30chemistries could be made to work with
- 37:32small samples was possible. And so, that
- 37:34was our our primary focus. And then when
- 37:37it became time to go into the clinical
- 37:39lab, we focused on putting them onto the
- 37:42specific hardware platforms that um we
- 37:45decided to put them on.
- 37:47So, were you kept apprised as to So, you
- 37:49said at some point um it was important
- 37:51to to actually validate the test.
- 37:54Yes.
- 37:54But were you apprised of that process
- 37:55and how many tests have been validated
- 37:57on the platforms?
- 38:02I think generally
- 38:04um yes. Um
- 38:07It just uh in terms of like the total
- 38:09number of tests that we were working to
- 38:11bring up in the lab initially is what
- 38:13I'm I'm thinking about.
- 38:17So, generally you were apprised of the
- 38:19number of tests that were validated on
- 38:21each of the platforms?
- 38:23I I don't think I knew specifically how
- 38:25many were on each platform. I knew
- 38:29for example, when we launched that
- 38:30generally we were working to bring up a
- 38:32menu of 70 tests on finger stick and we
- 38:34thought that would cover the ordering
- 38:36patterns we were going to see. I knew
- 38:37that there was, you know, certain
- 38:39general numbers on different platforms,
- 38:41but it wasn't like, okay, today, you
- 38:43know, something came up on this platform
- 38:45and I was alerted to that.
- 38:54Okay, and were there any areas, going
- 38:56back to my question about areas that you
- 38:58weren't familiar with to speak with
- 39:00investors about? Were there any areas
- 39:02that
- 39:03um
- 39:04you had an understanding Mr. Balwani
- 39:06wouldn't felt familiar with or
- 39:08comfortable talking to investors about?
- 39:11No.
- 39:14So, he would have been familiar with all
- 39:15aspects of the company, including for
- 39:17instance, the vision and the mission of
- 39:19the company as well?
- 39:21Yeah, I mean, he's he's very confident
- 39:23and he was confident that he was
- 39:28able to
- 39:30fill the role that he was in and
- 39:32um supplement the knowledge that he
- 39:35needed with other people.
- 39:50So, um
- 39:52you can put that aside now.
- 39:55So,
- 39:56I want to
- 39:57go back to
- 39:59um
- 40:03the 20 10 time period for the time
- 40:06being.
- 40:07Um and I want to start by asking sort of
- 40:11series of questions, but um
- 40:14you know, if I use the word analyzers,
- 40:15would you understand that that's what I
- 40:17mean is the device that's used to
- 40:18process blood tests?
- 40:22Yeah, I'd then ask you which
- 40:24which
- 40:24Which analyzer? Okay. So, I think we'll
- 40:26go through and um it would be helpful if
- 40:28if you could actually um explain what
- 40:31the different devices are and and the
- 40:33versions and
- 40:34um if I'm not being sufficiently clear,
- 40:36uh please let me know if I'm not being
- 40:37clear.
- 40:38Sure.
- 40:39Um so, in the 2010 time period, had
- 40:45I think you mentioned previously there
- 40:46were two devices that had been uh
- 40:50developed and that were in use. There
- 40:52was the 3.5
- 40:54MiniLab and the four-series MiniLab. Do
- 40:58you remember that testimony earlier?
- 41:00Yes.
- 41:00Okay.
- 41:01And just to be clear, that's referring
- 41:03to
- 41:05what I'm sort of generally referring to
- 41:06as this MiniLab family or the devices
- 41:09that were intended to be distributed.
- 41:11Okay.
- 41:12Um
- 41:16So,
- 41:19and then you mentioned there was also a
- 41:203.0, but that was similar to the 3.5
- 41:23version.
- 41:24Yes.
- 41:24But um but we're not sure as to
- 41:28what the difference
- 41:29the differences are between those two
- 41:31versions.
- 41:32Do you have any understanding?
- 41:34know specifically.
- 41:35Okay.
- 41:36Um
- 41:37So, starting with 3.5 machine, was that
- 41:40the machine that you believed would be
- 41:43used for clinical testing
- 41:45or was ready for clinical testing at
- 41:46that time?
- 41:48In 2010, we're talking about
- 41:50Yeah, I'm just talking about 2010.
- 41:52Um
- 41:54used for clinical What do you mean by
- 41:56used for clinical testing?
- 41:57Um
- 41:58well,
- 41:59you know,
- 42:00in 2010, were you
- 42:02thinking about getting into a
- 42:03relationship um with Walgreens and
- 42:06Safeway and thinking about rolling this
- 42:07out to retail pharmacy partners?
- 42:09We were.
- 42:10Okay. So, that's a clinical testing that
- 42:12I'm thinking of. So, uh
- 42:15um what kind of clinic what kind of
- 42:18Well, let me step back. So, the 3.5
- 42:20version, was that the version that you
- 42:22were um thinking would be used for
- 42:24clinical testing purposes at the retail
- 42:26pharmacies?
- 42:28At that time we believed it could be.
- 42:30Okay. You believed it could be. What do
- 42:32you mean by that?
- 42:34What what I understood as of that period
- 42:37of time is that the standards that were
- 42:39required to satisfy the assay criteria
- 42:43for a pharma trial
- 42:45were the FDA standards, I thought, and
- 42:48the FDA standards that meant you your
- 42:51data was good enough for clinical
- 42:52decision making. So,
- 42:54we believed that the exact process that
- 42:57we'd gone through for validating the
- 42:58assays there would allow it to be used
- 43:01in a clinical setting. We knew you would
- 43:02need to get the CLIA waiver and
- 43:05regulatory approval from the FDA.
- 43:07Okay.
- 43:08I'm sorry. So, you said you knew that
- 43:10you needed to get approval from the FDA.
- 43:12Yes.
- 43:13Before using it for clinical testing.
- 43:15Yes.
- 43:15This was back in 2010.
- 43:16setting.
- 43:17In a distributed setting. So, what do
- 43:19you mean by distributed setting?
- 43:21Outside of a certified clinical lab.
- 43:23Okay. And we're talking about 2010.
- 43:25Is that right?
- 43:27I I think so.
- 43:28Okay.
- 43:29I think so.
- 43:30Um and then you mentioned that your
- 43:31understanding as to how the machines
- 43:33needed to be validated was how they were
- 43:36validated for the
- 43:39uh clinical trials you were doing for
- 43:40pharmaceutical companies.
- 43:42Yes.
- 43:43How the tests were, yes.
- 43:44Okay. So,
- 43:45what was that validation process that
- 43:47you undertook
- 43:48for the pharmaceutical companies?
- 43:50Um there's it my understanding was that
- 43:52there's an FDA guidance document on a a
- 43:55series of steps. There's like 15 steps
- 43:58on sensitivity and specificity and other
- 44:01measurements um that ensure that the
- 44:04data
- 44:06is good enough to be used for clinical
- 44:09decision-making and at that time we
- 44:11thought that was
- 44:13what was in our development reports and
- 44:14what was going to be required for
- 44:17uh FDA submission.
- 44:20Okay. Um and who was in charge of the
- 44:22process of validating the devices to
- 44:24make them ready for clinical testing?
- 44:28Who was overseeing that process?
- 44:30Um in 2010?
- 44:32In 2010.
- 44:34Um
- 44:37I I don't know. We We always think about
- 44:39it in terms of tests, uh not devices,
- 44:42and it I I I again defer to
- 44:45um whoever was leading the assay
- 44:48initiatives at that time. Um
- 44:51Who was leading the assay initiatives?
- 44:53I I I can't remember in 2010. I don't
- 44:55know.
- 44:57Who would know who was in charge of that
- 44:59process?
- 45:01I I'm sure we can look back and and tell
- 45:03you. I I don't I don't know if Sunny
- 45:05would remember. Um
- 45:07I
- 45:08um
- 45:11We We could talk to some of our other
- 45:12scientists internally.
- 45:14Okay.
- 45:15And then uh on that version 3.5 minilab
- 45:19Yes.
- 45:19I think you mentioned uh previously
- 45:21earlier in testimony that that version
- 45:24could conduct You said tens of tests.
- 45:28I think so.
- 45:29Okay. What um and I think we we talked
- 45:32about how that was something less than
- 45:34100.
- 45:35Yes.
- 45:35What types of tests could it conduct?
- 45:38So that version of device was focused on
- 45:40a a method called immunochemistry um and
- 45:43it was running those
- 45:46types of tests for I I believe small
- 45:48molecules, proteins, um
- 45:53maybe metabolites, um
- 45:56and antibodies. I'm not completely sure.
- 45:59Um
- 46:00Um
- 46:03So what about and then I guess we talked
- 46:06a little bit about the 4 series as well,
- 46:07the 4 series mini lab. So, um I think
- 46:10you mentioned that that was in
- 46:11development and there were different
- 46:13sectors that were being developed in the
- 46:15machine. Do you remember that
- 46:16discussion?
- 46:17So, what was being done with the 4
- 46:19series mini lab?
- 46:22So, so the core
- 46:24of our invention
- 46:25was the concept of taking a robot
- 46:28that could replicate what a human does
- 46:31and putting it into a small box that
- 46:34could be used outside of a lab.
- 46:37The 3 series
- 46:39detected the signals from the
- 46:42chemistries
- 46:44through one form of detection called
- 46:47luminescence, which is measuring light,
- 46:50measuring photons.
- 46:51And what we wanted to do was add
- 46:54other
- 46:56detectors or capability of um other
- 47:00light forms like fluorescence. Um so, we
- 47:02were mounting other detectors around it
- 47:05and that's what the 4 series is.
- 47:07Okay. So, what could the 4 series test
- 47:10in terms of um like what were the
- 47:12numbers of tests that the 4 series could
- 47:14perform at that time?
- 47:16I I don't know. I
- 47:18I think we
- 47:21I I I'd be I'd be guessing.
- 47:24Yeah.
- 47:24Could it perform any number of tests?
- 47:27We had essentially and we my my memory
- 47:29is we had essentially shown
- 47:32proof of concept of the ability to do
- 47:35what I just said. I I don't know
- 47:40um how many chemistries we'd actually
- 47:42put on it um at that time.
- 47:49Yes. So,
- 47:50just to understand the the adding the
- 47:52additional
- 47:54set uh, let's say the fluorescence
- 47:56capability, Would Would that enable the
- 47:59uh, 4 series to to conduct tests in
- 48:02theory beyond the immunochemistry
- 48:05set?
- 48:06Is it Is that Is that a fair
- 48:07understanding?
- 48:08Yes, and most importantly,
- 48:11we were trying to invent a
- 48:13a a platform
- 48:15that could do
- 48:17you know, the the objective was anything
- 48:19that a lab could do. So, we needed the
- 48:22full range of
- 48:24options that are in a lab, so that if a
- 48:26test came along that we hadn't tried to
- 48:30develop yet, we had a box that could do
- 48:33it, right? Architecturally.
- 48:35And I mean, just broadly, what what kind
- 48:37of tests are immunochemistry tests?
- 48:40Um,
- 48:41so those are the ones I was talking
- 48:42about, proteins, antibodies, small
- 48:44molecules, drug levels, um, could be
- 48:47metabolites, um, essentially anything
- 48:49that you bind to with an antibody.
- 48:52And then, what were sort of
- 48:54other than the category of
- 48:55immunochemistry tests, what were the
- 48:56other kind of categories of tests that
- 48:58were sort of in that universe that you
- 48:59wanted to have the architecture for for
- 49:014 series?
- 49:01Yeah, and so just to be clear,
- 49:02immunochemistry is a method, right? It's
- 49:04not a category of tests. There's many
- 49:06different types of tests that can be
- 49:08done with the method of immunochemistry.
- 49:11Um,
- 49:12we wanted to
- 49:15um, we wanted to be able to do
- 49:19essentially a broad range of methods,
- 49:22right? So, we wanted to have a
- 49:25what's called a microscopy microscopy
- 49:27method for for imaging of cells. Um, we
- 49:30wanted to
- 49:32um,
- 49:35have um,
- 49:37fluorescence
- 49:39as a readout for measuring um,
- 49:43RNA and DNA for for pathogen detection.
- 49:46Um,
- 49:47and I I can list the other detectors
- 49:49that were in there and what they're for,
- 49:50if it's useful.
- 49:51Sure, that'd
- 49:53be great.
- 49:53Okay. So,
- 49:55um
- 49:57imaging, fluorescence, microscopy,
- 50:00um
- 50:02we we still had the luminescence
- 50:04capability,
- 50:06uh and absorbance.
- 50:08So, it's essentially the full range of
- 50:10readouts. What we're trying to do is
- 50:11take the lab and put it in a box.
- 50:18Did you have to use that phrase when
- 50:20when talking to other people, lab in a
- 50:22box?
- 50:25I'm I wouldn't be surprised if I did. I
- 50:27I can't sit here and say I remember
- 50:29specific conversation. Yeah,
- 50:31we most often talked about the concept
- 50:33of mini lab, which was miniaturized
- 50:35laboratory.
- 50:38Um
- 50:39so, I want to skip forward then to a few
- 50:41years later now, and we're talking again
- 50:43about 2013. So,
- 50:46tell us what devices Theranos had
- 50:49developed to process blood tests at that
- 50:51time.
- 50:54So, when the clinical lab went live,
- 50:58um
- 50:59which I believe was in
- 51:01um
- 51:03I I I think we did our our first sort of
- 51:06official patient testing around the end
- 51:07of October 2013.
- 51:10The date is probably not exact. Um
- 51:13we
- 51:14had both our
- 51:173.5 mini lab devices, as well as
- 51:21what we called at that time
- 51:23high-throughput
- 51:25platforms, which are open systems that
- 51:28you can put your proprietary protocols
- 51:32on
- 51:33to run small sample testing.
- 51:36And so, those included a number of
- 51:38different devices, one of which was the
- 51:41Advia 1800. Um
- 51:43there was a a
- 51:45cytometry one that was made by Beckton
- 51:47Beckton Dickinson and I believe there
- 51:49was a couple others.
- 51:51Okay, so just going back so you said
- 51:53there was the TSPU
- 51:54Mhm.
- 51:55um or the mini lab. What are we calling
- 51:57it at this time?
- 51:59At that time we were calling it the
- 52:01TSPU.
- 52:02Okay, so there was the TSPU, which
- 52:04version was it?
- 52:05I I believe that was the 3.5 version.
- 52:07It's still the 3.5 version. Okay, and
- 52:10how many tests could be run on the 3.5?
- 52:14Do you mean how many were run in the
- 52:15clinical lab or could be run?
- 52:17Uh I mean how many were validated to be
- 52:20run for clinical testing?
- 52:22Um I believe that
- 52:25we brought up about 15 in the clinical
- 52:27lab at that time.
- 52:29About 15?
- 52:30Yes.
- 52:31Okay, and what what time frame in 2013
- 52:33are you referring to when you say about
- 52:3515?
- 52:37Um I so I
- 52:38Are you thinking about before the launch
- 52:40of Theranos services in Walgreens?
- 52:43Um I was thinking of sort of the initial
- 52:45launch of the services in Walgreens. So
- 52:47it was um
- 52:49when the lab
- 52:50formally started seeing patients through
- 52:53to the next few months. Let's say 3 to 4
- 52:56months after. I'm not I don't know
- 52:57exactly when the tests were validated in
- 52:59that range.
- 53:00Okay.
- 53:00So you think about 15 tests were
- 53:02validated on the TSPU 3.5.
- 53:06Um and then you mentioned there were
- 53:08other open platforms including the Avia
- 53:111800, um some machine that was
- 53:13manufactured by What was it? Beckman?
- 53:16Yes.
- 53:17Um what's the name of the company?
- 53:19Not the Avia, but there was another one
- 53:21that was manufactured by Beckman
- 53:22Coulter.
- 53:23Coulter, okay. Um
- 53:25So what did what did Theranos do to
- 53:27those machines to
- 53:28It could have been Becton Dickinson. I'm
- 53:30sorry. I'm not sure, one of the two.
- 53:32Okay.
- 53:32One. Yeah.
- 53:33Um
- 53:34so what what had Theranos done to those
- 53:37open platform machines in order to
- 53:40um
- 53:42uh make it capable for these machines to
- 53:44be processing tests on smaller samples.
- 53:48Yeah, so different um modifications for
- 53:52different platforms.
- 53:53Um speaking about the Advia
- 53:56specifically,
- 53:57we had um taken our protocol, which is
- 54:02essentially our formula for how to make
- 54:04the chemistry work with the small
- 54:06volume,
- 54:07and
- 54:08as I understand it,
- 54:10overtaken essentially the the the
- 54:13software in the instrument to implement
- 54:15our protocol.
- 54:17Um and then we modified the physical
- 54:22hardware. There's little
- 54:23cups that are used to contain the
- 54:25sample, and one of the reasons that
- 54:27people take so much blood in blood
- 54:29testing is that those cups have a lot of
- 54:32loss. So, even though you only take out
- 54:35a tiny amount,
- 54:36you have to leave behind a lot of loss
- 54:38in the cup, and so we we changed the
- 54:41geometry so that you didn't have that
- 54:43loss, and
- 54:46then on other open platforms, like for
- 54:49the cells, it was our
- 54:51uh chemistries that were run on them,
- 54:54too. So, we actually made like the
- 54:57antibody in the chemistry that binded to
- 54:59the cell that lit up um to go into the
- 55:02assay.
- 55:02Okay. So,
- 55:04uh the Advia 1800, there is you
- 55:07mentioned a couple other machines that
- 55:08were made by another company. These were
- 55:10These were all uh
- 55:12machines that weren't manufactured by
- 55:14Theranos. Is that right?
- 55:17Correct. We purchased the machines and
- 55:19then we modified the hardware.
- 55:21We modified the hardware. So, um So, we
- 55:24might be talking about this a lot uh
- 55:26during today. So, if I said um if I
- 55:28refer to these machines as, you know,
- 55:30third-party commercially available
- 55:32machines, um would you understand that
- 55:35I'm talking about the Advia 1800,
- 55:37anything that with Theranos did not had
- 55:40not manufactured. Would you understand
- 55:42that?
- 55:43So, I
- 55:43I think it's important to distinguish
- 55:45that there were were also actual
- 55:46third-party commercial machines that
- 55:48were not modified that were in the
- 55:50laboratory as well. Okay. So, we had we
- 55:52had both platforms that we were doing
- 55:55hardware modifications as well as
- 55:57unmodified commercial machines.
- 55:59Okay. So, it sounds like there were
- 56:01three categories of of machines then,
- 56:03right? There is the TSPU 3.5 version
- 56:07that Theranos had manufactured. Is that
- 56:09right? And then there was the
- 56:12some third-party commercially available
- 56:14machines that Theranos had modified.
- 56:16Correct.
- 56:17And then there were also just other
- 56:18third-party
- 56:20commercially available machines that
- 56:22Theranos had purchased in order to
- 56:24conduct testing. Would that be via
- 56:26venous draw?
- 56:28Um yes.
- 56:29So, these machines would be conducting
- 56:31testing in in sort of the traditional
- 56:33venipuncture way.
- 56:35Yes, and I believe there was also a
- 56:37couple of
- 56:39um
- 56:40point-of-care devices that were in the
- 56:42lab like
- 56:43I don't think it was a glucose meter but
- 56:45kind of like a glucose meter.
- 56:47Um but they were commercial unmodified.
- 56:48You just wouldn't be putting venous
- 56:49blood on them.
- 56:51Does that make sense?
- 56:52Okay. Um I think I understand that.
- 56:55Can I ask for just a clarification on
- 56:56the um
- 56:57the um
- 57:00the hardware modified
- 57:01commercially available devices or that
- 57:03second category that that she just
- 57:05referenced.
- 57:05Yes.
- 57:06And you mentioned the hardware
- 57:07modification was I I guess that the
- 57:09modifications were sort of the software
- 57:11programming that the the machine and
- 57:13then the
- 57:14the geometry of the cup.
- 57:16Is that is that
- 57:17fair?
- 57:17Yes, and and on other instruments it was
- 57:22it was also our what I sometimes call
- 57:23chemistry, which is essentially we did
- 57:26the work to make
- 57:28the antibody or the binder and then we
- 57:30made all the other reagents like for the
- 57:33cytometry assays and then put them on
- 57:36these platforms that could then run our
- 57:39our tests.
- 57:40It
- 57:42you know earlier we sort of talked about
- 57:43the the idea of you know the consumable
- 57:45being
- 57:46you know what was put in the device. Is
- 57:49the is the is the modified geometry to
- 57:53lack of a better word on my part. Is
- 57:55that sort of also a consumable for for
- 57:58that platform?
- 57:59It is. I was speaking specifically to
- 58:02the conversation about the TSPU and what
- 58:06a consumable was to it but
- 58:08there's consumables there and there's
- 58:10other consumables like the nanotainers.
- 58:12And and is it is it would you consider
- 58:14the time a reagent to be a consumable as
- 58:17well?
- 58:18No. Okay.
- 58:20I don't think so. I mean I wouldn't now.
- 58:24So we've been going about an hour. Can
- 58:25we take another break? Short break?
- 58:27Sure.
- 58:28We're off the record at
- 58:2911:30.
- 58:40We are back on the record at 11:46.
- 58:43Ms. Holmes, did you have any substantive
- 58:45conversations with the SEC staff during
- 58:47break?
- 58:48I did not.
- 58:50So we were talking about modifying some
- 58:52of these third-party commercially
- 58:54available machines in order to test
- 58:57smaller samples before we left on the
- 58:59break. When was when were these machines
- 59:02modified?
- 59:06So I believe the
- 59:10the way the way I think about it is the
- 59:12implementation of our protocols onto
- 59:14them happened in 2013 before the
- 59:19clinical lab went live I I think.
- 59:22And why did Theranos have to develop
- 59:25these modified protocols
- 59:27uh during that time period?
- 59:30Um well, I'm just to be clear, the the
- 59:33protocols themselves date back to our
- 59:36original inventions in like 2005. Yeah,
- 59:39and the reason that we had to
- 59:42implement them on those
- 59:45open platforms was because
- 59:48we needed to process large numbers of
- 59:51samples in a centralized lab environment
- 59:54as opposed to the
- 59:55the TSPUs are designed to be near
- 59:58patient and process one sample at a
- 1:00:01time, and I think it takes
- 1:00:02like 30 minutes to an hour per sample,
- 1:00:05and we needed to be able to run a lot of
- 1:00:07samples at the same time in a
- 1:00:10centralized setting. So, that was why we
- 1:00:12were trying to figure out how to do this
- 1:00:14in a high-throughput way.
- 1:00:16So, the TSPU could only process one
- 1:00:18sample at a time?
- 1:00:19That's right.
- 1:00:20Okay. And you mentioned it How long
- 1:00:23would it take to process that sample?
- 1:00:25It It depends on the chemistry. It could
- 1:00:27be anywhere from
- 1:00:2818 minutes to an hour.
- 1:00:32Um and I think you mentioned uh
- 1:00:34It It could be different times, too. I
- 1:00:35mean, it varied per test.
- 1:00:37Okay.
- 1:00:38Um you mentioned before we took the
- 1:00:40break uh at the time in 2013 when you
- 1:00:43were getting ready to launch Theranos's
- 1:00:45services
- 1:00:47um through Walgreens that the TSPU
- 1:00:50was validated to run about 15 tests. Do
- 1:00:54you remember that earlier testimony?
- 1:00:57Um I I do, and and again, forgive me. I
- 1:01:00I think there were
- 1:01:0115 tests in the clinical lab that were
- 1:01:03validated on the TSPU, if that makes
- 1:01:06sense. Um
- 1:01:07Okay. What What was What was the
- 1:01:09distinction between what I was saying
- 1:01:10and what you were saying?
- 1:01:11Yeah. Yeah, sorry. Um
- 1:01:13the way that I think about it is that
- 1:01:15um
- 1:01:16the the TSPU itself
- 1:01:18we had thought at that time was
- 1:01:20validated to run a lot of tests, which
- 1:01:23you know, at one point we got up to
- 1:01:25about three over 300 chemistries that we
- 1:01:28developed and many of them, like 90 or
- 1:01:31so, I think were actually on the TSPU.
- 1:01:3415, we had validated as laboratory
- 1:01:37developed tests in the clinical lab as
- 1:01:40of that time, I believe.
- 1:01:42Okay, so just so that I'm clear and I
- 1:01:44understand what you're saying. So,
- 1:01:46you're saying there were about 300 or so
- 1:01:49that
- 1:01:50the TSPU was
- 1:01:52or that Theranos had developed assays
- 1:01:55for, right?
- 1:01:56Um about something I think we had talked
- 1:02:00about in 2010, something like less than
- 1:02:02100 were
- 1:02:04um
- 1:02:07Maybe you should explain it again
- 1:02:09because I'm not really understanding
- 1:02:10what the difference is between
- 1:02:12what was what was validated in 2010 and
- 1:02:14what was validated in 2013.
- 1:02:16Yeah, so so by the end of 2013, I
- 1:02:20believe that from a
- 1:02:22an R&D standpoint, about 90 or so
- 1:02:27uh
- 1:02:28tests had been
- 1:02:30we thought validated at that time on the
- 1:02:33TSPU.
- 1:02:34A subset of those
- 1:02:37went live in the clinical lab on the
- 1:02:40TSPU. I believe that was about 15
- 1:02:43around 2013.
- 1:02:46There were also other chemistries that
- 1:02:49we had developed that were running on
- 1:02:51other platforms beside the TSPU.
- 1:02:54Does that make sense?
- 1:02:55Okay, so 90 tests were validated to run
- 1:02:57on the TSPU in 2013.
- 1:03:00I believe so. About 90.
- 1:03:03Okay, but only 15 were being run in the
- 1:03:05clinical lab.
- 1:03:07Yes.
- 1:03:07Why weren't you running the other
- 1:03:11remaining tests
- 1:03:13out of the 90?
- 1:03:14We put
- 1:03:16Well, out of the 90
- 1:03:18Why weren't you running the other 75
- 1:03:20tests on the TSPU?
- 1:03:22So, the reasons changed over time.
- 1:03:24Around 2013, I think we were initially
- 1:03:27working to bring up in the clinical lab
- 1:03:30setting additional tests on the TSPU.
- 1:03:33And then at some point in time, we
- 1:03:34stopped and focused on the modified
- 1:03:38platforms as well as just trying to get
- 1:03:40those tests through the FDA
- 1:03:43so that they could be used in the phase
- 1:03:45two setting.
- 1:03:47Uh
- 1:03:48So, different the business model evolved
- 1:03:51and the strategy evolved.
- 1:03:53Okay. So, even though you had 90 tests
- 1:03:55validated on the TSPU, you decided only
- 1:03:58to run 15 on the TSPU because
- 1:04:03you had to get approval for the tests.
- 1:04:06And you you decided to
- 1:04:09uh focus more on the modified
- 1:04:12um protocol with the third-party
- 1:04:14commercially available machines.
- 1:04:16Yeah, so just um
- 1:04:18on that point, there were I believe
- 1:04:21about 90 development and validation
- 1:04:23reports with tests on the TSPU. Um
- 1:04:28the
- 1:04:29um
- 1:04:30the remainder
- 1:04:33we had done through
- 1:04:35uh other platforms. The subset of those
- 1:04:39went live in the clinical lab on the
- 1:04:40TSPU. Um the remainder of the focus in
- 1:04:44the clinical lab, as I understand it,
- 1:04:47was on the the systems that could
- 1:04:49process a lot of samples at the same
- 1:04:50time.
- 1:04:53I I I think there was some work to get
- 1:04:55more than 15 up. Um but I know that that
- 1:04:58work stopped and I I don't know when.
- 1:05:02You mentioned sort of the distinction
- 1:05:04between the the 15 tests that were
- 1:05:08ready to go as as LDTs versus the 90
- 1:05:10that were
- 1:05:11uh
- 1:05:12that were validated on the platform.
- 1:05:15In your mind, what was the difference
- 1:05:16between
- 1:05:18uh having a test be an LDT versus it
- 1:05:21being validated for the platform, I
- 1:05:23guess?
- 1:05:24Yeah.
- 1:05:24What what's the difference between the
- 1:05:25two?
- 1:05:26Sure. So, so when I use the words
- 1:05:28validated for the platform, I was
- 1:05:30referring to our understanding of the
- 1:05:33development guidelines that were
- 1:05:34required for these tests, namely the FDA
- 1:05:38assay development reference.
- 1:05:40The clinical lab had its own separate
- 1:05:43validation process for any tests that
- 1:05:46went live. And so, there were separate
- 1:05:48activities that were underway for each
- 1:05:51of those 15 prior to the lab director
- 1:05:54signing off on them.
- 1:05:56And did you have an understanding at the
- 1:05:57time about substantively what that
- 1:05:59meant? I mean,
- 1:06:01um in terms of I mean,
- 1:06:03what the folks in the lab were doing to
- 1:06:05No, I I knew that they had a separate
- 1:06:08validation process. I don't I I didn't
- 1:06:11know what the differences between the
- 1:06:12two were in in a substantive way.
- 1:06:20So, it sounds like there were two
- 1:06:23different kinds of validation processes
- 1:06:25that were
- 1:06:26um
- 1:06:27being performed on the TSP. The first
- 1:06:30was, according to what you said, the FDA
- 1:06:33guidelines.
- 1:06:35I think, you know, in in retrospect,
- 1:06:37it's what we had interpreted to be
- 1:06:41FDA's guidance document for assay
- 1:06:43development. And so, when I use the
- 1:06:45words developed and validated, that's
- 1:06:46what I'm referring to.
- 1:06:48Okay. But, you mentioned before um there
- 1:06:50were some characteristics of that
- 1:06:52validation process, including, you know,
- 1:06:54certain measures like
- 1:06:56test specificity and
- 1:06:58um precision and some of these other
- 1:07:01categories. That was what your
- 1:07:02understanding was with respect to
- 1:07:05um how to validate the device under the
- 1:07:08FDA guidelines.
- 1:07:11Yes, those are elements of that process
- 1:07:14and then there were certain criteria
- 1:07:16that were acceptable um
- 1:07:19for each of those sets of experiments
- 1:07:22that we had used that guidance document
- 1:07:25as an indicator of making sure that we
- 1:07:27were
- 1:07:28as good as we had wanted to be.
- 1:07:30Okay. And then, um, you mentioned there
- 1:07:33was a separate validation procedure that
- 1:07:35the CLIA lab was doing.
- 1:07:38Is that right?
- 1:07:39Okay. And and so
- 1:07:41as of 2013, only 15 tests had been
- 1:07:45validated under the CLIA procedure.
- 1:07:48Correct.
- 1:07:49On the TSPU.
- 1:07:50Yes.
- 1:07:51I I think.
- 1:07:52But you're
- 1:07:53But you have no understanding as to what
- 1:07:55that CLIA procedure for validation is.
- 1:07:59My My understanding is that it's
- 1:08:01similar, but that there's some parts
- 1:08:03that are different and that
- 1:08:05it's specific to
- 1:08:08um
- 1:08:11uh essentially what the lab director
- 1:08:14determines are the acceptance criteria
- 1:08:16for a lab-developed test. I I don't know
- 1:08:19specifically what aspects were differing
- 1:08:21from our our own development and
- 1:08:23validation of the assays.
- 1:08:26Okay. And then, going back to then the
- 1:08:29third-party commercially available
- 1:08:31machines that uh Theranos had modified
- 1:08:35uh how many tests could those machines
- 1:08:38perform?
- 1:08:40And just so I answer the question best,
- 1:08:42um
- 1:08:44could they perform meaning how many LDTs
- 1:08:47had we validated in the clinical lab on
- 1:08:48them?
- 1:08:49Yes.
- 1:08:49Um I I believe there was
- 1:08:53um about 60 or so. Um I'm I'm not sure
- 1:08:56what the exact number was.
- 1:08:59Okay, so about 15 were validated, um,
- 1:09:02pursuant to the clear procedure on the
- 1:09:04TSPU at that time, and 60 were on the
- 1:09:07modified commercially available
- 1:09:09machines.
- 1:09:10Yes.
- 1:09:10Okay. And then
- 1:09:12Just to be clear, those numbers are not
- 1:09:13exact, but it's about those numbers. I
- 1:09:16don't know the exact numbers.
- 1:09:18Okay. But in terms of the number, you
- 1:09:20think it would be something less than
- 1:09:21100 on the modified machines?
- 1:09:23I do.
- 1:09:24Okay. And then in terms of the third
- 1:09:26category of machines, which would have
- 1:09:28been just the regular third-party
- 1:09:31commercially available machines that
- 1:09:32were running Venus blood.
- 1:09:34Mhm.
- 1:09:34Um how many tests could those that those
- 1:09:37machines perform?
- 1:09:39Would Would it just be the remainder of
- 1:09:40the tests that Theranos is offering?
- 1:09:43Um well, we ran the remainder either on
- 1:09:45those or by sending out to the reference
- 1:09:48labs.
- 1:09:49Um and I don't know exactly how many
- 1:09:51were on the the commercial machines.
- 1:09:53Okay. But they would either be performed
- 1:09:55on the third-party commercially
- 1:09:56available machines or they would be sent
- 1:09:58out to reference labs.
- 1:09:58Correct. Yes.
- 1:10:01Just a couple of clarifications there.
- 1:10:02So, the the 15 or so that were on the
- 1:10:05TSPU and the the 60 or so that were on
- 1:10:07the modified commercially available, are
- 1:10:10those mutually exclusive sets or is
- 1:10:12there any overlap between
- 1:10:14the LDTs on those platforms?
- 1:10:16question. Um
- 1:10:18I think the way we're counting them,
- 1:10:20it's mutually exclusive. We We
- 1:10:24So,
- 1:10:25the open platforms were capable of
- 1:10:28running a couple of the tests that we
- 1:10:30put on the TSPU. I don't know whether we
- 1:10:32ever ran them on both. I think for the
- 1:10:34purpose of this discussion, it's okay to
- 1:10:36consider them as different tests.
- 1:10:40Um and then you sort of just thinking
- 1:10:42thinking back through your answer about
- 1:10:44the
- 1:10:45you understood that there were 15 LDTs
- 1:10:47that were that were on the TSPU. There
- 1:10:49were there were about 90, again,
- 1:10:52ballpark, that were validated in your in
- 1:10:55the company's view with on the TSPU.
- 1:10:58No. Oh, sorry. Yeah.
- 1:10:59Um what was there
- 1:11:01was there ever a situation where uh
- 1:11:04someone at the company told you that
- 1:11:05additional LDTs weren't being brought
- 1:11:08onto the
- 1:11:09TSPU because of
- 1:11:11challenges in in uh
- 1:11:13in getting those
- 1:11:15you know, one of those 90 validated
- 1:11:18to the Theranos understanding
- 1:11:20tests up to the LDT standard.
- 1:11:25I
- 1:11:27So, I can't remember any specific
- 1:11:28conversations. I I knew that there were
- 1:11:32ongoing
- 1:11:33sort of initiatives and and challenges
- 1:11:35in general in bringing LDTs up, but I
- 1:11:38thought that
- 1:11:40the fact that our lab director had
- 1:11:41signed off on the reports for the first
- 1:11:4315 meant that there were no fundamental
- 1:11:47issues in the ability to bring up more
- 1:11:50tests, and um certainly believed that uh
- 1:11:54you know, as we worked to then take
- 1:11:56those
- 1:11:58um same tests that we'd done the
- 1:12:00development on
- 1:12:01into the pre-submission process for FDA.
- 1:12:53I'm handing to you what's been marked
- 1:12:55there as Exhibit 197.
- 1:13:05Is that 3419?
- 1:13:09Exhibit 197
- 1:13:13purports to be a June 11th, 2013 email
- 1:13:18from Sunny Balwani to Elizabeth Holmes.
- 1:13:21The subject line is forward demo next
- 1:13:23Tuesday, 6/11 at noon with starting
- 1:13:27Bates number ATS-0902539.
- 1:13:32Have you seen Exhibit 197 before?
- 1:13:37I don't know. I I don't remember it. Um
- 1:13:40I'm not sure.
- 1:13:44Is this your email address at Theranos,
- 1:13:46[email protected]?
- 1:13:48It is.
- 1:13:48Do you have any reason to believe that
- 1:13:50you might not have received this?
- 1:13:51I don't.
- 1:13:53Uh what is this email about?
- 1:13:57Do you mind if I take just a second to
- 1:13:59read this?
- 1:14:43It looks like it's an exchange on
- 1:14:46um
- 1:14:49trying to do a a demonstration of
- 1:14:52one of the mini lab devices.
- 1:14:54Okay.
- 1:14:55Um and do you recall who that
- 1:14:57demonstration was for?
- 1:14:58No.
- 1:15:00So, if you look at the initial email on
- 1:15:02the bottom of um
- 1:15:04the the second page, which is 540,
- 1:15:08he's writing to uh Do you have that
- 1:15:10email?
- 1:15:11I do.
- 1:15:12Uh and he states or he writes, rather,
- 1:15:14"Sunny mentioned that he'd like to run a
- 1:15:16demo during an exec meeting next
- 1:15:18Tuesday. It runs from 12:00 to p.m. in
- 1:15:20our office here."
- 1:15:22Do you
- 1:15:23know what he's referring to when he says
- 1:15:24exec meeting?
- 1:15:26I don't.
- 1:15:27Is exec short for executive?
- 1:15:29I I'm assuming so, yes.
- 1:15:31And did you have executive meetings at
- 1:15:33Theranos?
- 1:15:36Leslie, I'm not quite sure what is an
- 1:15:38what an executive meeting is. Um
- 1:15:41I I currently hold executive team
- 1:15:43meetings. I I don't think that's what
- 1:15:45this is referring to.
- 1:15:46Okay. Do you think it might be referring
- 1:15:48to a meeting with
- 1:15:50a business partner
- 1:15:52or someone from the outside?
- 1:15:54I I'd be guessing. I have no idea.
- 1:15:56So,
- 1:16:02So, if you then flip to the first page
- 1:16:05at 539,
- 1:16:07you'll see that um
- 1:16:10as they're setting up this
- 1:16:11demonstration, he's then writing on June
- 1:16:1310th
- 1:16:15to
- 1:16:16um a number of individuals at the
- 1:16:18company, including and he's copying
- 1:16:19Sunny Balwani at the bottom. He says,
- 1:16:21"For tomorrow's demo as listed below,
- 1:16:22we'd like to have a mini lab in either a
- 1:16:254S or Monobay
- 1:16:27uh with the Normandy shell uploaded,
- 1:16:29whichever works better." So, he's
- 1:16:31mentioning a number of different um
- 1:16:33devices. Uh
- 1:16:35there's the 4S and the Monobay.
- 1:16:38Do you know what he's talking about
- 1:16:40here?
- 1:16:43So, I'm I'm not sure specifically. I
- 1:16:46think
- 1:16:48just looking at the chain here in the
- 1:16:49reference to mobile labs up above that
- 1:16:52he's distinguishing 4S as the
- 1:16:56device that we'd been investing in
- 1:16:59uh for
- 1:17:00the DoD deployments that we had wanted
- 1:17:02to do
- 1:17:03uh and the mono bay as uh the version of
- 1:17:06it which
- 1:17:07we later began to think about as the
- 1:17:10uh um the mini lab that could be used at
- 1:17:13at retail or physician offices.
- 1:17:15What was the difference between the 4S
- 1:17:17and the mono bay?
- 1:17:18The 4S was designed to be much more
- 1:17:20compact and to try to um be developed to
- 1:17:24some of the standards that were set by
- 1:17:26special operations command for things
- 1:17:29that could be lifted and transported uh
- 1:17:32in
- 1:17:33a way that their command could handle
- 1:17:35and it also had a lot of investment in
- 1:17:37things like vibration mounts
- 1:17:39um to make it more robust for use in
- 1:17:43more um
- 1:17:46uh
- 1:17:46difficult settings.
- 1:17:48Okay. And then what and so how is the
- 1:17:50mono bay different from that?
- 1:17:52It was not intended to be used in
- 1:17:56um
- 1:17:57sort of more extreme environments. It
- 1:17:59was designed for sort of a
- 1:18:01routine
- 1:18:02uh
- 1:18:03clinical setting kind of like our
- 1:18:05wellness centers.
- 1:18:07Uh
- 1:18:08so in other words, it was was it bigger
- 1:18:11than than the 4S?
- 1:18:13I think it was bigger, but it also it
- 1:18:15just didn't have the same vibration
- 1:18:17control and other things that would
- 1:18:19ultimately be required if you were going
- 1:18:21to do those types of
- 1:18:22um deployments the DoD was interested
- 1:18:25in.
- 1:18:25Were there any differences in
- 1:18:27capabilities between the two devices?
- 1:18:31I don't know. I I there might have been.
- 1:18:33I'm I'm I'm sure there was. I I don't
- 1:18:35remember specifically what.
- 1:18:38Uh
- 1:18:39who would know the answer to that
- 1:18:39question?
- 1:18:42Um
- 1:18:46I'm just looking at the email to
- 1:18:52I don't know specifically. Um
- 1:18:56the product teams that were working on
- 1:18:57it at the time
- 1:18:59who's listed here
- 1:19:01um
- 1:19:02I'm sure would have known what this was
- 1:19:04referring to at the time.
- 1:19:07Okay. And when mentions the Normandy
- 1:19:10shell being uploaded onto the machine,
- 1:19:12did you understand what he meant by
- 1:19:13that?
- 1:19:16I'm not completely sure what he means by
- 1:19:18that. I
- 1:19:20It's a It's a piece of software and I
- 1:19:22don't
- 1:19:24know why he wants to put that software
- 1:19:26on it. It must have been for some type
- 1:19:27of demonstration purposes.
- 1:19:29What is the Normandy shell?
- 1:19:32I don't know.
- 1:19:33I'm not sure.
- 1:19:35So, you just said it's a piece of
- 1:19:36software. Did she know what the software
- 1:19:38did?
- 1:19:39I don't. I know that there was a
- 1:19:40reference I know it's software because
- 1:19:42it says Normandy shell and so that is
- 1:19:44probably some type of shell software
- 1:19:46system. I don't know
- 1:19:48what code it refers to it.
- 1:19:50It might be
- 1:19:53a version of the software that allows
- 1:19:54you to report results from the device,
- 1:19:56but I'm I'm purely
- 1:19:58guessing based on looking at the email
- 1:20:00now.
- 1:20:01What is Normandy?
- 1:20:04Um Normandy is a word that was used to
- 1:20:06refer to a number of different projects
- 1:20:09internally in so far as I was familiar
- 1:20:11with it. It referred to
- 1:20:14the concept of having samples sent to a
- 1:20:18central lab through the nanotainer in
- 1:20:20phase one of our sort of business model.
- 1:20:24Um and then later deploying the device.
- 1:20:26I know Sunny used it in the software
- 1:20:29setting and I think even in the lab
- 1:20:31setting for a number of
- 1:20:33different
- 1:20:34uh purposes. I'm not quite sure exactly
- 1:20:36all the use cases.
- 1:20:40So, if you look at the response then
- 1:20:42back from, which is just about email,
- 1:20:45he says, "I've just finished getting the
- 1:20:47device OS installed with Normandy app
- 1:20:50and properly running the null protocol
- 1:20:53on mobile labs for an eight."
- 1:20:56So, what did you understand him to be
- 1:20:57saying there?
- 1:21:02Are you just sort of figuring out
- 1:21:03whether I should to interpret the
- 1:21:05document now, or you asking whether it
- 1:21:07refreshes a recollection going back to
- 1:21:09that time period?
- 1:21:10I'm asking her what her I mean, it
- 1:21:13sounds like she doesn't necessarily
- 1:21:15recall this this email, but I'm asking
- 1:21:18what her understanding is of what's
- 1:21:19being written in this email now.
- 1:21:22Yeah, I mean, looking at it now,
- 1:21:24um
- 1:21:27it says he's installed software on it.
- 1:21:30And I I don't know what the null
- 1:21:31protocol was. Um
- 1:21:35and
- 1:21:36I think that the mobile labs is a
- 1:21:38reference to
- 1:21:40the version of 4S at that time, but I'm
- 1:21:42not sure.
- 1:21:43So, you don't know what null protocol is
- 1:21:45referring to?
- 1:21:46I don't.
- 1:21:47Have you ever heard that um
- 1:21:50that phrase before?
- 1:21:53I don't recognize it. I may have heard
- 1:21:55it before. Um I'm not
- 1:21:58I don't know what it is.
- 1:21:59Okay.
- 1:22:00Um
- 1:22:00I I would guess it's a test protocol,
- 1:22:01but I'm not sure.
- 1:22:02What do you mean by test protocol?
- 1:22:05A lot of times when you want to make
- 1:22:06sure that the instrument is functioning
- 1:22:08properly, you have a it's kind of like a
- 1:22:10QC protocol or a a test protocol that
- 1:22:13allows you to ensure that whatever
- 1:22:16software you've installed or
- 1:22:18um whatever configuration you've put the
- 1:22:19device in, it it operates properly.
- 1:22:22Okay. Did you ever conduct
- 1:22:23demonstrations where um a blood sample
- 1:22:26was actually put into a device and the
- 1:22:29device, you know, tested the blood
- 1:22:31sample.
- 1:22:33Did you ever
- 1:22:35conduct an a demonstration like that?
- 1:22:37Yes.
- 1:22:38When when did you do that?
- 1:22:41Very frequently. I'm
- 1:22:44and
- 1:22:45many times over
- 1:22:47all the years.
- 1:22:48And
- 1:22:49would you, you know, after putting the
- 1:22:51blood sample into the device, would that
- 1:22:53device then generate a result?
- 1:22:57If we put a blood sample into it?
- 1:22:59Yes.
- 1:23:00If it was programmed to, yes.
- 1:23:02And were there times where you generated
- 1:23:04that result while, you know, whoever you
- 1:23:06were conducting that demonstration for
- 1:23:08was present?
- 1:23:09Yes.
- 1:23:10And who do you recall doing that for?
- 1:23:14Well, I know we gave
- 1:23:16one of the early versions of the mini
- 1:23:17lab to Walgreens to keep at their
- 1:23:20headquarters so that they could do that
- 1:23:21themselves whenever they wanted. I'm
- 1:23:26I I don't have specific
- 1:23:29recollections of the meeting, but I I
- 1:23:32believe we
- 1:23:34I'm
- 1:23:35brought devices to at least Safeway to
- 1:23:38use in their conference room and run
- 1:23:40samples on when we were first forming
- 1:23:42that relationship. I'm I know
- 1:23:46we would do it
- 1:23:48I'm
- 1:23:51we we've done it for I'm board members a
- 1:23:54few times when whenever it was a
- 1:23:56relevant part of talking about that part
- 1:23:58of our our business model.
- 1:24:01Do you ever recall instances where you
- 1:24:05uh
- 1:24:08where you instructed others at Theranos
- 1:24:10to
- 1:24:12um run a program on the devices so that
- 1:24:15it would look like the machine was
- 1:24:17running even though it wasn't actually
- 1:24:19processing a test?
- 1:24:22We have test protocols that essentially
- 1:24:24allow you to show the device um
- 1:24:27functioning. Um we
- 1:24:30will do that in a lot, including for
- 1:24:32open systems of the
- 1:24:34open demonstrations of the device where
- 1:24:36you want people to see the architecture.
- 1:24:38Okay.
- 1:24:38Um so it it runs essentially a
- 1:24:42for lack of a better word, dummy
- 1:24:42protocol. Um so that you can see how the
- 1:24:46inside of the instrument moves or
- 1:24:48see the user interface or those types of
- 1:24:50things.
- 1:24:51Right. So even if it's not processing a
- 1:24:53test, you you would be able to see that
- 1:24:54the machine is actually running inside.
- 1:24:57Is that what a test protocol is for?
- 1:24:59Either running inside or seeing how the
- 1:25:01software GUI works on the outside.
- 1:25:05Uh and do you recall using those test
- 1:25:07protocols a lot during your
- 1:25:09demonstrations?
- 1:25:12I mean again, we would
- 1:25:13do demonstrations in response to
- 1:25:16questions or interest in certain parts
- 1:25:18of the system. So
- 1:25:21um
- 1:25:22we do it a lot now because we show
- 1:25:25open sort of versions of the device to
- 1:25:27show people the architecture. I know we
- 1:25:29did it at at certain points in time in
- 1:25:32the past, depending on what the context
- 1:25:34of the meeting was and what people were
- 1:25:36interested in seeing about the device.
- 1:25:39What Was there a name for So in those
- 1:25:41instances in which you were actually
- 1:25:43testing a blood sample and it's going
- 1:25:45into machine, was there a name for the
- 1:25:47program or the software that would be
- 1:25:48uploaded to the machine in order to do
- 1:25:50that?
- 1:25:52I don't know.
- 1:25:53I don't know.
- 1:25:54Who would know the answer to that
- 1:25:55question?
- 1:25:57Name for the
- 1:25:59the software to run the test protocol? I
- 1:26:01I would say that
- 1:26:02talking about uh the instance It's It
- 1:26:03sounds like from what what I understand
- 1:26:06what you've just been saying is that the
- 1:26:08test protocol is something that can be
- 1:26:09put on the machine to
- 1:26:11to sort of mimic how the machine would
- 1:26:14work if it was testing uh a sample, but
- 1:26:17is there a separate program that would
- 1:26:19be put on a machine in the case that
- 1:26:21you're conducting an
- 1:26:23a demonstration where you're actually
- 1:26:24putting in a blood sample?
- 1:26:28Um,
- 1:26:29so if you're putting in a blood sample
- 1:26:31and you're reporting a test result, then
- 1:26:33the test result will be specific to
- 1:26:36whatever chemistry is on that cartridge
- 1:26:38and that's what's reported out
- 1:26:41to the end user in the end.
- 1:26:44If you're
- 1:26:46I'm not I'm not quite sure.
- 1:26:49So, maybe I don't understand how the
- 1:26:51machines work. Are they already as a
- 1:26:53default program to conduct tests on
- 1:26:56blood samples? So, in other words, you
- 1:26:59would put the blood sample in, the
- 1:27:00machine would conduct the test, and the
- 1:27:03test result would be generated?
- 1:27:06Um, so the way that our
- 1:27:09TSPU systems work is that on each
- 1:27:11cartridge there's a barcode and that
- 1:27:13barcode can be specific to a chemistry
- 1:27:16that's loaded into the cartridge. It
- 1:27:17could be specific to a test protocol,
- 1:27:21like a QC protocol or if it was going to
- 1:27:24go through the movements but not
- 1:27:25actually run an actual chemistry.
- 1:27:28And
- 1:27:30um
- 1:27:32anything else that you would want the
- 1:27:33instrument to do. So, it would be
- 1:27:34determined by whatever on the cartridge.
- 1:27:37If that makes sense, whatever barcode is
- 1:27:38on the cartridge.
- 1:27:41So, the barcode on the cartridge
- 1:27:43determines whether it's running one
- 1:27:45protocol versus another?
- 1:27:46Yes.
- 1:27:48So, when you're talking about the test
- 1:27:50protocol, it's is it not a software
- 1:27:53that's being loaded onto the device?
- 1:27:57I I'm not aware of soft So, there's an
- 1:28:00operating system on the device. The
- 1:28:02protocol
- 1:28:04I believe the barcode calls a server and
- 1:28:07then it determines what protocol to run
- 1:28:10based on what's on the barcode.
- 1:28:14Okay. Um then if you look back at the at
- 1:28:17exhibit 197 then
- 1:28:21um
- 1:28:22responds uh that same day
- 1:28:26and he says, "Right now we're not
- 1:28:27planning to run anything on the mini
- 1:28:30lab, unfortunately. Um the general
- 1:28:33chemistry and ELISA assays are not
- 1:28:36performing adequately for a demo at the
- 1:28:38moment."
- 1:28:39Um
- 1:28:40so it
- 1:28:41is that right? Is ML referring to the
- 1:28:43mini lab?
- 1:28:46I I think so given the references here
- 1:28:49to mobile labs and mini lab. I'm not
- 1:28:52quite sure exactly what it's referring
- 1:28:53to, but it could be.
- 1:28:55Okay. And so he's referring he's
- 1:28:57actually responding back to Sunny
- 1:28:58Balwani's question um about what you're
- 1:29:01planning to run on the ML. Do you see
- 1:29:03that?
- 1:29:04I do.
- 1:29:05Okay. Um so
- 1:29:09it sounds like the general chemistry and
- 1:29:11the ELISA assays were not performing um
- 1:29:14or or
- 1:29:16were not
- 1:29:17I guess performing accurately or
- 1:29:18adequately on the mini lab at that time.
- 1:29:21Does that refresh your recollection that
- 1:29:24the mini lab was not actually performing
- 1:29:27assays in this timeframe?
- 1:29:29It it doesn't. I mean there's there's a
- 1:29:31lot of reasons why
- 1:29:33they could have had issues with it. We
- 1:29:35would
- 1:29:35as you know been doing immunochemistries
- 1:29:38for many years on
- 1:29:40earlier versions of this platform.
- 1:29:42Okay, but they're actually talking about
- 1:29:44the 4S and the Monobay.
- 1:29:47I don't
- 1:29:47Was it So is it your understanding that
- 1:29:49the 4S and the Monobay could conduct
- 1:29:51testing?
- 1:29:54Yes.
- 1:29:56How many tests could We we had this
- 1:29:58conversation earlier, but how many tests
- 1:30:00could the 4S or the four series mini lab
- 1:30:03perform?
- 1:30:05My understanding was that we were going
- 1:30:07through the process to take all of the
- 1:30:09chemistries that we'd developed, the the
- 1:30:11few hundred that we were talking about,
- 1:30:13and put them onto the four
- 1:30:17series platform. I don't know
- 1:30:19which of these this is referring to and
- 1:30:21begin the process of getting them into
- 1:30:23the FDA later in 2013.
- 1:30:26Okay. And so, was it your understanding
- 1:30:28then that
- 1:30:30those tests were validated on the
- 1:30:32MiniLab 4S?
- 1:30:35The development and validation work I
- 1:30:36don't think was on the 4S device, but it
- 1:30:38was my understanding that the validation
- 1:30:40on the three series translated to the
- 1:30:42four series. So, you would have to run
- 1:30:45it again on the four series hardware,
- 1:30:47but it was essentially the same
- 1:30:48architecture of a a robot moving fluid
- 1:30:51around now with more uh detectors for
- 1:30:54different readouts.
- 1:30:56So, I mean maybe I don't understand. So,
- 1:30:58are
- 1:31:01was the four was the MiniLab 4S
- 1:31:04performing any tests in 2013? Was it
- 1:31:07capable of performing any tests?
- 1:31:10I thought it was. I mean I'm I'm saying
- 1:31:13that just based on
- 1:31:15remembering engaging with the FDA. We
- 1:31:17brought it to the FDA and we
- 1:31:19began the pre-submission process on it
- 1:31:21with the FDA that year.
- 1:31:23And had you validated those tests on the
- 1:31:26MiniLab 4S?
- 1:31:28Again, I think the the development and
- 1:31:30validation reports were on earlier
- 1:31:32iterations of the hardware, but we
- 1:31:35um believed and I believed that you
- 1:31:38could
- 1:31:39basically take the same chemistry that's
- 1:31:40been created and run it on this
- 1:31:42iteration of the hardware. Just to be
- 1:31:44clear, you said 4S. I'm speaking
- 1:31:47generally about MiniLab. I don't know if
- 1:31:49it was 4S or another version of the four
- 1:31:52series platform.
- 1:31:53Okay. Um I think probably we should
- 1:31:56clarify that we're when we're talking
- 1:31:57about the MiniLab, at least with With to
- 1:32:00this email, we're talking about the four
- 1:32:01series.
- 1:32:02Yeah, exactly.
- 1:32:03Okay.
- 1:32:04Um okay, so you think that maybe during
- 1:32:07this time frame there were some issues
- 1:32:09with being able to adequately perform
- 1:32:12the uh general chemistry or Eliza assays
- 1:32:15on the Mini Lab 4S, but that generally
- 1:32:17speaking
- 1:32:19your understanding was that these
- 1:32:20devices could conduct the test?
- 1:32:23My understanding was that
- 1:32:25architecturally what we had created with
- 1:32:27the four series from a hardware
- 1:32:29perspective
- 1:32:30was sound and that all the chemistries
- 1:32:33that we'd made over the years
- 1:32:35could be put on it and taken through the
- 1:32:38FDA as we later did with HSV which got
- 1:32:42cleared. And I I certainly knew that
- 1:32:45like with any
- 1:32:47you know, new technology that was coming
- 1:32:48up, there would be issues.
- 1:32:50Um but
- 1:32:51I I was never aware that there were any
- 1:32:53showstoppers in being able to do that
- 1:32:56with the four series platform.
- 1:33:06Okay, you can put that one aside.
- 1:33:41So, I'm going to hand to you
- 1:33:44what's been marked there in this exhibit
- 1:33:46198.
- 1:33:54This is tab four.
- 1:33:58Is that at 198? purports to be a January
- 1:34:0123rd, 2014 email
- 1:34:04from to Elizabeth Holmes with a copy to
- 1:34:08a number of individuals. Starting Bates
- 1:34:10number is TS-0469692.
- 1:34:14Have you seen exhibit 198 before?
- 1:34:19I I I recognize it. I I don't know if
- 1:34:21I've seen it since sending it, but I
- 1:34:23recognize it.
- 1:34:25What is exhibit 198?
- 1:34:27Um it's an email exchange between me and
- 1:34:30with the FDA.
- 1:34:34So, if you look at your initial email
- 1:34:37um on January 22nd,
- 1:34:402014, you're noting
- 1:34:43in your email
- 1:34:45um
- 1:34:46I think you're getting ready to provide
- 1:34:47a copy
- 1:34:48of some updated plans for some
- 1:34:51pre-submissions to the FDA. Do you see
- 1:34:53that?
- 1:34:55I'm sorry, where are you?
- 1:34:56Uh your your email to
- 1:34:58Okay.
- 1:34:59Do you see that you're providing him
- 1:35:00with a copy of an updated plan?
- 1:35:02Yes.
- 1:35:02That's in the first sentence of your
- 1:35:03email.
- 1:35:04Yes.
- 1:35:04Uh you then say for your reference as of
- 1:35:06now, uh vit D, is that short for vitamin
- 1:35:09D?
- 1:35:10Yes.
- 1:35:11Uh TSH, PSA, and FT4 Eliza assays are
- 1:35:16the only assays run through the Theranos
- 1:35:18processing device in Theranos's CLEA lab
- 1:35:21on patient samples collected at Theranos
- 1:35:23wellness centers.
- 1:35:24Was that consistent with your
- 1:35:25understanding that uh
- 1:35:28there were only four tests that were
- 1:35:30being run on the Theranos uh
- 1:35:34I guess the TSPU from patient samples
- 1:35:36being obtained from the wellness
- 1:35:39wellness centers at Walgreens?
- 1:35:41I'm I'm sure it was at that time. We
- 1:35:43were making sure to keep the FDA
- 1:35:45completely apprised of everything we
- 1:35:47were doing.
- 1:35:49Okay.
- 1:35:50Um do you know why only four of the
- 1:35:52assays were being run on the TSP during
- 1:35:54this time and this is January of 2014?
- 1:35:58I I don't. If all 15 of them had been
- 1:36:01brought up by then, then this is
- 1:36:02probably just based on the orders we and
- 1:36:05we also hadn't really seen that many
- 1:36:07patients on fingerstick by this period
- 1:36:08of time.
- 1:36:13Do the um
- 1:36:15was there a time when uh
- 1:36:17the number of tests that were being
- 1:36:19performed on the TSP changed? Was it
- 1:36:22just a matter of bringing the the next
- 1:36:25you know,
- 1:36:26uh 11 or so tests online and having them
- 1:36:29validated?
- 1:36:32No. Um
- 1:36:34we generally looked at this based on
- 1:36:37ordering patterns and
- 1:36:39our belief was and and still is that
- 1:36:42about 70 assays will cover al- almost
- 1:36:46100% of the orders that um you'll get
- 1:36:50from the types of prac- physician
- 1:36:52practices that we were trying to serve.
- 1:36:54Um so
- 1:36:56the goal was to match that test menu.
- 1:37:00As I said earlier, I think there was a
- 1:37:01period of time in which we thought more
- 1:37:03than 15 would go up. I know that that
- 1:37:05changed and I'm not sure exactly when it
- 1:37:07changed, but um
- 1:37:10we weren't necessarily just linearly
- 1:37:12looking at bringing up more assays on an
- 1:37:15ongoing basis.
- 1:37:16Okay. So, what is your understanding as
- 1:37:18to the maximum number of tests that the
- 1:37:20TSP ever performed on patient samples
- 1:37:23from Walgreens?
- 1:37:24I I think it's that 15 number. Yeah.
- 1:37:34You can put that one aside.
- 1:37:44FlexSure.
- 1:38:01I'm handing to you what's been marked
- 1:38:03Theranos Exhibit 199.
- 1:38:14So, is there a difference here that
- 1:38:16binds two-sided and there's
- 1:38:17Yes, that's That's why it looks a little
- 1:38:18thicker.
- 1:38:19Um
- 1:38:21Exhibit 199 purports to be
- 1:38:25Defendant Theranos Inc.'s
- 1:38:28uh responses and objections to
- 1:38:29Plaintiff's first set of interrogatories
- 1:38:32that were filed uh in the Court of
- 1:38:34Chancery of the State of Delaware in the
- 1:38:37Partner Investments LP versus Theranos
- 1:38:40Inc.
- 1:38:42case.
- 1:38:44Have you seen Exhibit 199 before?
- 1:38:49I don't know.
- 1:38:51I I might have.
- 1:38:55Are you aware that there was a lawsuit
- 1:38:57that was filed by Partner Investments
- 1:38:59and uh PFM Healthcare Master Fund
- 1:39:02against Theranos?
- 1:39:03Yes.
- 1:39:07Would you have been involved and were
- 1:39:09you involved in preparing responses to
- 1:39:11their um
- 1:39:14uh interrogatories?
- 1:39:16I certainly was engaged with our legal
- 1:39:19team on
- 1:39:20responding to them. I I don't know what
- 1:39:22my specific role was in
- 1:39:24responding to the interrogatories. I'm
- 1:39:26sure I talked with our team about it.
- 1:39:29I I may have seen some of the documents.
- 1:39:30I I don't have a specific memory of
- 1:39:33you know, what exact documents I looked
- 1:39:34at sitting here.
- 1:39:35Sure.
- 1:39:36Um if you could just turn to
- 1:39:39page with Bates number ending 3465.
- 1:39:48And just for the record, the starting
- 1:39:49Bates number on this document is
- 1:39:51SEC-PRN-E-0003430.
- 1:39:57So, are you on
- 1:39:59uh 3465?
- 1:40:01Yes.
- 1:40:01Okay. So, here in interrogatory number
- 1:40:0415, uh Theranos has submitted a response
- 1:40:07and looks like PFM is asking the about
- 1:40:12the number of um
- 1:40:15blood tests that were being processed
- 1:40:17through the TSPU beginning in January
- 1:40:201st, 2013
- 1:40:23for clinical uh patient testing. Do you
- 1:40:25see the the response here?
- 1:40:28I I do.
- 1:40:28Okay. And Theranos response that there
- 1:40:30are a number of tests that were being
- 1:40:32performed on the TSPU and by my count,
- 1:40:34there are about 12 of them.
- 1:40:36Uh that start and those that list starts
- 1:40:39in at 3465 and ends on 3466.
- 1:40:44Yes.
- 1:40:44You see that? Is that consistent with
- 1:40:46your understanding of the tests that
- 1:40:48were performed on the TSPU?
- 1:40:55Um
- 1:40:56yeah, and I I don't have any reason to
- 1:40:58doubt this.
- 1:41:00And
- 1:41:00at looking at the list, were there any
- 1:41:02other tests that you believed were being
- 1:41:05tested or performed on the TSPU that
- 1:41:08aren't being listed here?
- 1:41:11You know, if there's 12 here, I had the
- 1:41:12number 15 in my head. It may have been
- 1:41:15that
- 1:41:16either they weren't up by this period of
- 1:41:18time or they were never run, they were
- 1:41:20validated, or I could be wrong about the
- 1:41:2115 number, I'm not sure.
- 1:41:23Okay. So,
- 1:41:24do you have any reason to believe that
- 1:41:26um
- 1:41:27only
- 1:41:28otherwise, that only tests that only 12
- 1:41:30tests were being performed on the TSPU?
- 1:41:34I don't know. I if if that's what this
- 1:41:37says, I don't have any reason to doubt
- 1:41:38it.
- 1:41:39Okay.
- 1:41:40Did you ever share the fact that the
- 1:41:42TSPU was um
- 1:41:45only performing about 12 tests
- 1:41:48with Walgreens?
- 1:41:51I I don't
- 1:41:54I don't think so. I don't know.
- 1:41:58You're not aware of an instance in which
- 1:42:00you might have told Walgreens that the
- 1:42:01TSPU was only performing 12 tests?
- 1:42:03I I'm not.
- 1:42:07Are you aware of ever informing Safeway
- 1:42:10that the TSPU was performing 12 tests in
- 1:42:12this time frame, 2013?
- 1:42:15I mean, after the Clear Lab went live, I
- 1:42:17don't think we had any discussions with
- 1:42:19them about
- 1:42:21what we were doing in the clinical lab.
- 1:42:24Did you ever uh share or did you ever
- 1:42:27discuss the fact that the TSPU was
- 1:42:29performing about 12 tests with Sunny
- 1:42:31Balwani?
- 1:42:34I I can't remember a specific discussion
- 1:42:36about it. Yeah, I'm I I know there were
- 1:42:39discussions that we had about
- 1:42:42sort of
- 1:42:44stopping using the three series
- 1:42:45platform, working to get the four series
- 1:42:47into the FDA, and then our
- 1:42:50our hope and goal was that we would be
- 1:42:51putting all the tests on that platform
- 1:42:53as fast as we could.
- 1:42:55Okay. So, do you know whether Mr.
- 1:42:57Balwani knew that the TSPU was only
- 1:42:59running something like 12 or 15 tests
- 1:43:02at the time?
- 1:43:04I I don't know. Um but I I assume he
- 1:43:07would have.
- 1:43:08Um why do you say that you assume he
- 1:43:10would have?
- 1:43:11Because he was managing the clinical
- 1:43:12lab.
- 1:43:14Um what about others at the company?
- 1:43:17Um
- 1:43:18did you ever discuss the fact that the
- 1:43:19TSPU was running about 12 tests with,
- 1:43:22for instance,
- 1:43:23I I don't think I ever had a specific
- 1:43:26discussion about the number of tests on
- 1:43:28the TSPU with him that I I recall. Um
- 1:43:32Uh we had a lot of discussions about
- 1:43:35technology and including the TSPU. So,
- 1:43:38it may have been an element of the
- 1:43:39discussion, but I can't remember a
- 1:43:41specific discussion about it only
- 1:43:42running 12.
- 1:43:44What about the project manager? Did she
- 1:43:46ever discuss with them the fact that the
- 1:43:48TSP was running something like 12 to 15
- 1:43:50tests?
- 1:43:53I I don't think so. I mean, what the
- 1:43:55chemistries were running on in the
- 1:43:57clinical lab was not a focus of
- 1:43:59any of our discussions internally or or
- 1:44:01really externally at at that point in
- 1:44:03time.
- 1:44:04Why wasn't it a focus of discussions?
- 1:44:07Because in phase one of our model, it
- 1:44:08was about the chemistries. It was about
- 1:44:10redeveloping the assays to work with
- 1:44:12small volumes. And then phase two
- 1:44:15was about use of the the TSPU in a
- 1:44:17distributed setting. And
- 1:44:19that was the vision. That was what we
- 1:44:21were spending most of our time working
- 1:44:22on. But how we operationalized the tests
- 1:44:25in the clinical lab
- 1:44:27in the meantime was was just not
- 1:44:31not something that any of us really
- 1:44:33focused on very much
- 1:44:35in in conversation.
- 1:44:36So,
- 1:44:37so can you explain for me I guess what
- 1:44:40why Theranos decided to pursue
- 1:44:42commercial testing in phase one. So, so
- 1:44:45so I I I think I understand what you you
- 1:44:46described there. Phase one is about
- 1:44:48getting the chemistries ready. Phase two
- 1:44:49is about the TSPU being out there.
- 1:44:52W- why conduct commercial testing in in
- 1:44:55phase one at all?
- 1:44:57Yeah, so um
- 1:45:01I I think there's there's two parts to
- 1:45:03that. Um the first is um
- 1:45:07our business model
- 1:45:09shifted when we formed the partnership
- 1:45:12after we formed the partnership with the
- 1:45:13retail pharmacies. And there was a lot
- 1:45:16of discussion about getting CLIA waiver
- 1:45:19on the devices and a concern about how
- 1:45:22long that would take and the regulatory
- 1:45:24model for it. No one had done this
- 1:45:27before.
- 1:45:28And so, the decision was made to become
- 1:45:30a clinical lab. The concept with phase
- 1:45:32one was that the value is the retail
- 1:45:36footprint, right? Bringing lab to the
- 1:45:38retail footprint. And you've seen now
- 1:45:41Quest and LabCorp, you know, immediately
- 1:45:43go partner with
- 1:45:45Walgreens and Walmart to to do that.
- 1:45:48To the extent we were focused on small
- 1:45:50samples, we invented the nanotainer
- 1:45:53to be able to work with the chemistries
- 1:45:56that we had redeveloped for small
- 1:45:57assays. And that was the concept for
- 1:46:00fingerstick-based testing in phase one.
- 1:46:02In phase two,
- 1:46:04the value proposition was to bring the
- 1:46:06device to the wellness centers to get
- 1:46:08tests even faster. And so, that's what
- 1:46:12TSPU was about because it processed one
- 1:46:15sample at a time. And in phase one, you
- 1:46:17were going to have a lot of samples
- 1:46:19coming in at the same time.
- 1:46:20So,
- 1:46:21phase one was retail footprint, access,
- 1:46:23low cost, transparent pricing, the $4
- 1:46:26lab test concept. And then to the extent
- 1:46:28you were doing small samples, the
- 1:46:30nanotainer implemented with our
- 1:46:32chemistries.
- 1:46:33And then phase two was
- 1:46:36distribute the device, right? And and
- 1:46:37phase two
- 1:46:39was what we really wanted to do and is
- 1:46:41what we're
- 1:46:42still trying to do right now.
- 1:46:47Is there a business plan or anything
- 1:46:48that articulated that?
- 1:46:50What you just
- 1:46:51I'm
- 1:46:52not in a
- 1:46:55systematic way at that time. We
- 1:46:58did not have um
- 1:47:03organized documents the way we do now
- 1:47:05that really lay all of this out.
- 1:47:16Can you put that aside?
- 1:47:18Actually, let's make a separate pile.
- 1:47:21Put there. Thanks.
- 1:47:59Let me see what's been marked. There it
- 1:48:02is. Exhibit 200.
- 1:48:11Just tab that.
- 1:48:17Exhibit 200
- 1:48:19reports to be Defendant Theranos Inc.'s
- 1:48:22first supplemental responses and
- 1:48:23objections to Plaintiff's first set of
- 1:48:25interrogatories
- 1:48:27uh in the filed in the Court of Chancery
- 1:48:30of the State of Delaware in the Partner
- 1:48:32Investments versus Theranos Inc. case
- 1:48:35with starting Bates number
- 1:48:36SEC-PRM-E-0005120.
- 1:48:42Have you seen Exhibit 200 before?
- 1:48:46I don't know. Um but again, I I I worked
- 1:48:49with our legal teams as we worked to
- 1:48:52respond to CFM.
- 1:48:58So, if you take a look at 5128,
- 1:49:07there's a supplemental response to that
- 1:49:08same interrogatory that we were just
- 1:49:10looking at
- 1:49:12in Exhibit 199.
- 1:49:14Interrogatory number 15.
- 1:49:16Mhm.
- 1:49:16Um and it says here, "By way of further
- 1:49:19response, Theranos states the version
- 1:49:213.5 of the SPU is the only version of
- 1:49:23the SPU used since January 1st, 2013 to
- 1:49:27process blood tests for commercial
- 1:49:28testing certain patients." And that's
- 1:49:30consistent with your understanding that
- 1:49:31the TSPU version 3.5 was the only device
- 1:49:34ever used for patient testing. Is that
- 1:49:36right?
- 1:49:38The only
- 1:49:40version of the mini lab family that was
- 1:49:42used, yes.
- 1:49:42The only device manufactured by Theranos
- 1:49:45is that that was used for patient
- 1:49:46testing, is that right?
- 1:49:48Um,
- 1:49:49that's right. And just for the sake of
- 1:49:52being explicit, we we considered
- 1:49:55the we actually injection molded and
- 1:49:57made the little cups that went into the
- 1:49:59hardware ourselves in our factory. So,
- 1:50:01we considered ourselves as manufacturing
- 1:50:03some elements of the hardware for the
- 1:50:05other platforms as well.
- 1:50:06Okay. So, the sample cups that you were
- 1:50:08using with the Abaxis 100, they those
- 1:50:12were Theranos manufactured cups.
- 1:50:15We We made them. Yep.
- 1:50:17What were those called internally at the
- 1:50:18time?
- 1:50:20So, I don't know. Um, I've seen a lot of
- 1:50:23references to
- 1:50:24different um
- 1:50:27words used, I think, in describing the
- 1:50:28general concept. Um, I've seen the word
- 1:50:31teacup. I I don't know if that
- 1:50:34um explicitly refers to what I'm
- 1:50:36referring to. I I had understood that to
- 1:50:38refer to Theranos cup. Um, but I I could
- 1:50:41be wrong about that.
- 1:50:46Okay. Um,
- 1:50:49and then if you turn to
- 1:50:55And actually, um, yeah, turning to the
- 1:50:57next page, 5129.
- 1:51:02Actually, at the bottom of 5128, if you
- 1:51:04want to follow through, it says, "By
- 1:51:05further By way of further response,
- 1:51:07Theranos identifies all other iterations
- 1:51:09of the SPU since January 1st, 2013 as
- 1:51:13follows and then there's a list on 5129.
- 1:51:17Um which lists, you know, 3.0, the 4.0,
- 1:51:21the mini lab tower, the 4S, and the 4.1.
- 1:51:26Um
- 1:51:27if you take a quick review of that
- 1:51:29of the descriptions of all of those
- 1:51:31versions, is this consistent with your
- 1:51:33understanding of
- 1:51:35those versions and what they were used
- 1:51:37for?
- 1:51:43I I I think so generally. I I don't have
- 1:51:46any reason to doubt it.
- 1:51:47Okay.
- 1:51:49Um and what did the TSPU
- 1:51:52look like? And maybe they were different
- 1:51:55they looked differently, so what did the
- 1:51:573.5 look like?
- 1:52:00So they all
- 1:52:01look like a box with a screen on it uh
- 1:52:04with a hole on the front that has a door
- 1:52:07and you can stick um what we call a
- 1:52:10cartridge, which is the piece of plastic
- 1:52:11that has all the chemicals in it, into
- 1:52:14it um and the cartridge has a little
- 1:52:17hole where you can put samples, so you
- 1:52:19can put urine or you can put blood from
- 1:52:22your arm, or you can put the little
- 1:52:23nanotainers with the finger stick in
- 1:52:25there.
- 1:52:26And you said they all look very
- 1:52:28similarly.
- 1:52:30Generally, yes.
- 1:52:31Generally.
- 1:52:32Um
- 1:52:33what was the size of one of the 3.5s?
- 1:52:38What were the dimensions what were the
- 1:52:39what were the were the dimensions of
- 1:52:41that
- 1:52:41I I don't I don't know the specific
- 1:52:43dimensions, but we would sort of refer
- 1:52:45to it as being similar in size to a a
- 1:52:48desktop computer that you would have
- 1:52:49under your desk.
- 1:52:52Um and then turning to 5155
- 1:52:59and exhibit 200.
- 1:53:14You'll see there's a supplementer a
- 1:53:16supplemental response in interrogatory
- 1:53:18number 27. Do you see that?
- 1:53:21I do.
- 1:53:21Um and what PFM is asking Theranos is to
- 1:53:25identify any non-proprietary or
- 1:53:27commercially available machine equipment
- 1:53:29or technology that you use to perform
- 1:53:30tests.
- 1:53:33Do you see that?
- 1:53:34Yes.
- 1:53:34Okay. And on the next page, Theranos
- 1:53:36provides its response with a table
- 1:53:39devices purchased from third parties and
- 1:53:41it goes from 5156 to 5158.
- 1:53:47Is this consistent with your
- 1:53:48understanding of the third party devices
- 1:53:51that Theranos was using to conduct
- 1:53:53patient testing?
- 1:53:55You know, I I wouldn't know um but I
- 1:53:57don't have reason to doubt this
- 1:53:58document.
- 1:54:04And was that also your understanding um
- 1:54:06you know, in 2014 that this was as as of
- 1:54:092013 or since January 1st, 2013 but
- 1:54:14um would this list be uh of devices that
- 1:54:17were were being used by Theranos that
- 1:54:19were purchased from third party
- 1:54:22companies? Was that consistent with your
- 1:54:24understanding as of 2014?
- 1:54:27Again, I wouldn't know. I I
- 1:54:29didn't have direct involvement in what
- 1:54:31devices were being procured for the
- 1:54:33clinical lab.
- 1:54:34But you don't have any reason to believe
- 1:54:35that um this information is incorrect as
- 1:54:37of 2014 either.
- 1:54:41I I don't know. I I don't know. I know
- 1:54:43that the business model shifted.
- 1:54:46Um I know that as of a period of time we
- 1:54:48were
- 1:54:50understanding the value proposition on
- 1:54:53low cost and therefore trying to achieve
- 1:54:56automation and standardization in the
- 1:54:57clinical lab. So there was a big
- 1:54:59investment in standardizing on Siemens
- 1:55:01equipment. I don't know when exactly
- 1:55:03that happened, so it
- 1:55:05I'm
- 1:55:06these might have been different in in
- 1:55:08different periods of time.
- 1:55:11Do you want to switch the tape?
- 1:55:17We break for lunch at 12:30 today.
- 1:55:20We've got 2 minutes left on this.
- 1:55:21Yeah.
- 1:55:21Yeah. No, why don't we Why don't we
- 1:55:23switch the tape? If you guys don't mind,
- 1:55:25go ahead and switch the tape. We are off
- 1:55:27the record and
- 1:55:28This concludes media number two of
- 1:55:30Elizabeth Holmes. We're off the record
- 1:55:31at 12:43.
- 1:55:34Um
- 1:55:36Let me just
About this transcript
This page contains the full transcript of Elizabeth Holmes SEC Deposition JULY 11, 2017 2 OF 4 redacted by ANTL Media, generated from the public captions YouTube serves with the video. The transcript has 16,016 words across 2,977 segments, with the original timestamps preserved so you can click any line to jump to that moment in the embedded player.
What you can do with it
Use the transcript to take notes, quote the speaker, build a study guide, generate a summary with ChatGPT or Claude via the YouTube Summary tool, or export it as a timed subtitle file with YouTube to SRT. You can also re-open it in the transcriber to choose a caption track available on the video.
Free YouTube transcript tool
YouTube2Text is a free YouTube transcript generator — no signup, no daily limit. Paste any YouTube link and get the full transcript instantly, with timestamps, click-to-jump, caption language selection, AI prompts for ChatGPT, Claude, and Gemini, and exports to TXT, SRT, VTT, or Markdown.